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General Information.  Unless stated otherwise, reactions were performed at ambient tempera-
ture (23 °C) in flame-dried glassware under an argon atmosphere using dry, deoxygentated sol-
vents (distilled or passed over a column of activated alumina) (43).  Commercially available 
reagents were used as received.  Reactions requiring external heat were modulated to the speci-
fied temperatures using an IKAmag temperature controller.  Thin-layer chromatography (TLC) 
was performed using E. Merck silica gel 60 F254 pre-coated plates (250 nm) and visualized by 
UV fluorescence quenching or potassium permanganate staining.  Silicycle SiliaFlash P60 Acad-
emic Silica gel (particle size 40–63 nm) was used for flash chromatography. Purified water was 
obtained using a Barnstead NANOpure Infinity UV/UF system.  1H and 13C NMR spectra were 
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recorded on a Varian Inova 500 (500 MHz and 126 MHz, respectively) and a Bruker AV III HD 
spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz and 101 
MHz, respectively) and are reported in terms of chemical shift relative to CHCl3 (δ 7.26 and 
77.16, respectively).  19F and 31P NMR spectra were recorded on a Varian Inova 300 (282 MHz 
and 121 MHz, respectively).  Data for 1H NMR spectra are reported as follows: chemical shift (δ 
ppm) (multiplicity, coupling constant, integration).  Infrared (IR) spectra were recorded on a 
Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of absorption (cm-1). 
Analytical chiral SFC was performed with a Mettler SFC supercritical CO2 analytical chro-
matography system with Chiralpak (AD-H) or Chiracel (OD-H) columns obtained from Daicel 
Chemical Industries, Ltd.  High resolution mass spectra (HRMS) were obtained from the Caltech 
Center for Catalysis and Chemical Synthesis using an Agilent 6200 series TOF with an Agilent 
G1978A Multimode source in mixed (Multimode ESI/APCI) ionization mode. Optical rotations 
were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. For X-
Ray structure determination, low-temperature diffraction data (-and -scans) were collected on a 
Bruker AXS D8 VENTURE KAPPA diffractometer coupled to a PHOTON 100 CMOS detector 
with K radiation ( = 1.54178 Å) from an IμS micro-source for the structure of compound 
P17208. The structure was solved by direct methods using SHELXS (44) and refined against F2 
on all data by full-matrix least squares with SHELXL-2014 (45) using established refinement 
techniques (46).  All non-hydrogen atoms were refined anisotropically.  All hydrogen atoms were 
included into the model at geometrically calculated positions and refined using a riding model. 
The isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value 
of the atoms they are linked to (1.5 times for methyl groups).  Unless otherwise noted, all disor-
dered atoms were refined with the help of similarity restraints on the 1,2- and 1,3-distances and 
displacement parameters as well as rigid bond restraints for anisotropic displacement parameters. 
Compound P17208 crystallizes in the orthorhombic space group P21212 with one molecule in the 
asymmetric unit along with two molecules of isopropanol.  The hydroxide group and both iso-
propanol molecules were disordered over two positions.  The Flack parameter refines to be 
0.138(9). 
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Synthesis of Isoquinoline-N-Oxide 9. 
3,5-dimethoxy-4-methylbenzaldehyde (S2).  The procedure was adapted from the method of 
Comins et al. (47).  N-methylpiperazine (670 µL, 6.6 mmol, 1.1 equiv) was dissolved in 20 mL 
THF and cooled to –20 ºC.  n-Butyllithium (2.4 M, 2.65 mL, 6.3 mmol, 1.05 equiv) was added in 
a dropwise fashion, resulting in an orange solution.  The solution was stirred at this temperature 
15 min before a solution of 3,5-dimethoxybenzaldehyde (S1, 1.00 g, 6.0 mmol, 1 equiv) in 3 mL 
THF was added in a dropwise fashion, causing a color change to yellow.  The solution was 
stirred at this temperature 30 min before a second portion of n-butyllithium (2.4 M, 7.5 mL, 18.1 
mmol, 3 equiv) was added in a dropwise fashion.  At this point, the flask was stored in a –20 ºC 
freezer for 24 h.  The flask was re-submerged in a –20 ºC bath, and freshly distilled methyl io-
dide (2.25 mL, 36.1 mmol, 6 equiv) was added in a dropwise fashion, resulting in a mild 
exotherm.  The solution was stirred 30 min at –20 ºC and was removed from its bath, warming to 
room temperature.  After 30 min the reaction was quenched by the addition of 20 mL 0.5 M HCl, 
and the solution was stirred 30 min open to air.  The layers were separated and the aqueous phase 
was saturated with sodium chloride.  The aqueous phase was extracted with Et2O, dried over 
MgSO4 and concentrated.  The product was purified by column chromatography (10% EtOAc/
hex).  Colorless solid, 1.03 g, 5.72 mmol, 95% yield.  NMR spectra were identical to the previ-
ously reported compound (47).  1H NMR (400 MHz, CDCl3) δ 9.88 (s, 1H), 7.03 (s, 2H), 3.87 (s, 
6H), 2.14 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 192.0, 158.7, 135.1, 122.5, 104.7, 55.9, 9.0. 
Note:  This procedure could be readily increased to 10 g scale with minimal loss in yield (>90% 
yield). 
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2-Bromo-3,5-dimethoxy-4-methylbenzaldehyde (11).  Aldehyde S2 (8.62 g, 47.8 mmol, 1 
equiv) was dissolved in CH2Cl2 (100 mL, 0.5 M) and acetic acid (30 µL, 0.5 mmol, 0.01 equiv) 
was added.  The solution was cooled to 0 ºC before bromine was added in a slow, dropwise fash-
ion.  The solution was stirred 30 min after complete addition at 0 ºC, at which time TLC (10% 
EtOAc/hex) showed complete conversion.  The reaction was quenched by the addition of 10% 
aqueous sodium thiosulfate and saturated NaHCO3 solution.  The layers were separated and the 
aqueous phase was extracted with CHCl3.  The combined organic phases were washed with wa-
ter, dried over MgSO4 and concentrated.  The product was purified by dissolving in ~50 mL boil-
ing hexanes, under which conditions the trace amounts of dibromide are insoluble.  The solution 
was filtered while boiling, providing the pure product.  Colorless solid, 10.13 g, 39.1 mmol, 82% 
yield.  NMR spectra were identical to the previously reported compound (48).  1H NMR (400 
MHz, CDCl3) δ 10.33 (s, 1H), 7.21 (s, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 2.25 (s, 3H);  13C NMR 
(101 MHz, CDCl3) δ 191.8, 158.2, 156.2, 132.2, 129.5, 114.9, 106.0, 60.8, 56.1, 10.6.  
(E)-2-(3-((tert-butyldimethylsilyl)oxy)prop-1-yn-1-yl)-3,5-dimethoxy-4-methylbenzalde-
hyde oxime (13).  Bromide 11 (19.4 g, 74.9 mmol, 1 equiv), (PPh3)2PdCl2 (2.6 g, 3.70 mmol, 
0.05 equiv), and CuI (714 mg, 3.75 mmol, 0.05 equiv) were slurried in diisopropylamine (300 
mL, 0.25 M, freshly distilled from CaH2) in a 2 liter 3-necked roundbottom flask, and the orange 
suspension was sparged with N2 for 10 min.  O-tert-butyldimethylsilyl propargyl alcohol (12, 
17.3 g, 101 mmol, 1.35 equiv) (49) was added in one portion, causing the suspension to darken 
as the palladium catalyst was reduced.  The suspension was sparged with N2 for a further 1 min, 
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then heated to 70 ºC for 24 h.  At this stage, TLC and LCMS indicated complete conversion of 
bromide 11, so the suspension was cooled to 50 ºC and 200 mL MeOH was added.  Hydroxy-
lamine hydrochloride (6.24 g, 89.8 mmol, 1.2 equiv) was added in one portion and the solution 
was heated to reflux (85 ºC) for 2 h.  At this stage, TLC and LCMS indicated complete conver-
sion to the product.  The solution was cooled to room temperature and celite (~100 g) was added. 
The suspension was filtered through a pad of celite, topped with sand, eluting with ethyl acetate. 
The filtrate was concentrated and purified by column chromatography (15% EtOAc/hex).  Color-
less solid, 26.9 g, 74.1 mmol, 99% yield.  1H NMR (500 MHz, CDCl3) δ 8.60 (s, 1H), 7.46 (s, 
1H), 7.10 (s, 1H), 4.62 (s, 2H), 3.86 (s, 6H), 2.15 (s, 3H), 0.95 (s, 9H), 0.18 (s, 6H); 13C NMR 
(126 MHz, CDCl3) δ 160.5, 158.8, 149.5, 132.8, 122.5, 110.3, 101.9, 96.2, 78.2, 61.0, 55.9, 52.6, 
26.0, 18.5, 9.3, –5.0; IR (thin film, NaCl):  3270.1, 3092.6, 2997.3, 1953.8, 2932.4, 2896.1, 
2857.0, 2221.2, 1611.1, 1591.7, 1560.0, 1463.8, 1402.9, 1383.9, 1331.8, 1281.5, 1255.3, 1217.9, 
1191.5, 1164.3, 1136.9, 1121.1, 1101.2, 1080.0, 1034.8, 977.1, 903.5, 837.9, 779.7, 722.1, 704.2, 
671.8; HRMS (ESI-TOF) calc’d for [M+] C19H29NO4Si = 363.1866, found 363.1939. 
3-(((tert-butyldimethylsilyl)oxy)methyl)-5,7-dimethoxy-6-methylisoquinoline-N-oxide (9). 
Oxime 13 (15.92 g, 45.7 mmol, 1 equiv) was dissolved in CH2Cl2 (460 mL, 0.1 M) and the flask 
was vacuum purged and refilled with nitrogen five times, then heated to reflux.  AgOTf (235 mg, 
0.91 mmol, 0.02 equiv) was added in one portion to the refluxing solution, resulting in a rapid 
and mildly exothermic reaction.  The reaction flask was shielded from light and maintained at 
reflux for 15 min, at which time LCMS indicated full conversion to the product.  The solution 
was filtered through a 1 inch pad of silica with 500 mL CH2Cl2 and 1 L 10% MeOH/EtOAc.  Sil-
ica gel (40 mL) was added to the second portion of filtrate, which was then concentrated.  The 
product was purified by column chromatography using a 6 inch pad of silica (30–50–100% 
EtOAc/CH2Cl2; then 2–5–10–20% MeOH/EtOAc + 1% NEt3).  Colorless solid, 12.27 g, 33.8 
mmol, 77% yield.  The product is initially isolated as a black solid that is spectroscopically pure, 
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and can be recrystallized to a colorless solid from minimal boiling heptanes.  Very little mass is 
lost during this process (less than 50 mg from a 12 g batch), indicating the presence of very mi-
nor yet highly colored impurities. 1H NMR (400 MHz, CDCl3) δ 8.65 (s, 1H), 8.02 (s, 1H), 6.71 
(s, 1H), 5.01 (d, J = 1.4 Hz, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 2.27 (s, 3H), 1.00 (s, 9H), 0.15 (s, 
6H); 13C NMR (101 MHz, CDCl3) δ 159.4, 153.7, 145.9, 135.2, 128.4, 123.6, 120.1, 115.0, 97.4, 
61.7, 60.1, 55.9, 26.0, 18.4, 9.8, -5.3; IR (thin film, NaCl):  3390.3, 3073.7, 2998.1, 2953.8, 
2892.2, 2857.2, 1637.3, 1613.4, 1567.8, 1470.6, 1390.6, 1371.6, 1341.4, 1308.3, 1254.2, 1209.7, 
1185.3, 1148.0, 1116.4, 1020.7, 1007.1, 957.4, 899.7, 838.8, 808.0, 777.9, 701.7, 669.8, 637.7; 
HRMS (ESI-TOF) calc’d for [M+] C19H29NO4Si = 363.1866, found 363.1863. 
Synthesis of Isoquinoline Triflate 10. 
3,4-Dimethoxy-5-methylphenyl isopropylcarbamate (S4).  In a nitrogen-filled glovebox, 
[Ir(cod)OMe]2 (22.3 mg, 0.034 mmol, 0.005 equiv) and 3,4,7,8-tetramethyl-1,10-phenanthroline 
(15.9 mg, 0.067 mmol, 0.01 equiv) were dissolved in 5 mL THF and stirred 30 min.  In the 
meantime, 2,3-dimethoxytoluene (1.00 mL, 6.73 mmol, 1 equiv) and B2Pin2 (1.28 g, 5.05 mmol, 
0.75 equiv) were weighed into a 20 mL sealable microwave vial (also in the glovebox) with a 
teflon-coated stir bar and 5 mL THF was added.  Upon complete dissolution, the catalyst solution 
was transferred to the microwave vial, which was sealed prior to removing from the glovebox. 
The vial was then placed in a preheated 80 ºC oil bath and stirred 48 h, at which time TLC (20% 
EtOAc/hex) revealed complete conversion to a single borylated product.  The vial was cooled to 
room temperature and the cap was removed.  N-methylmorpholine-N-oxide (2.37 g, 20.2 mmol, 
3 equiv) was added in a few small portions and the vial was resealed and returned to the 80 ºC oil 
bath for 3 h, at which time TLC (20% EtOAc/hex) indicated complete oxidation to the interme-
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diate phenol.  Triethylamine (4.7 mL, 33.7 mmol, 5 equiv) and isopropyl isocyanate (2.6 mL, 
26.9 mmol, 4 equiv) were added at 23 ºC and the solution was stirred 16 h, at which time TLC 
(50% EtOAc/hex) indicated complete conversion to carbamate S4.  The contents of the vial were 
transferred to a 100 mL roundbottom flask and 10% aq. Na2S2O3 was added to quench the re-
maining oxidant and citric acid hydrate (4.5 g, >3 equiv) was added to chelate the boron.  This 
solution was stirred 1 h, and concentrated HCl was added 1 mL at a time until an acidic pH was 
achieved.  The layers were separated and the aqueous phase was extracted with EtOAc.  The 
combined organic phases were then washed with aqueous K2CO3, dried over MgSO4 and con-
centrated.  The product was purified by column chromatography (25% EtOAc/hex).  Colorless 
solid, 1.16 g, 4.6 mmol, 68% yield.  NMR spectra were identical to the previously reported com-
pound (49).  1H NMR (400 MHz, CDCl3) δ 6.55 (d, J = 2.6 Hz, 1H), 6.52 (d, J = 2.8 Hz, 1H), 
4.84 (d, J = 7.8 Hz, 1H), 3.88 (ddd, J = 16.1, 13.9, 7.6 Hz, 1H), 3.82 (s, 3H) 3.76 (s, 3H), 2.24 (s, 
3H), 1.23 (s, 3H), 1.21 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 154.0, 153.0, 146.8, 144.7, 132.3, 
115.4, 104.3, 60.3, 55.9, 43.6, 23.0, 16.0. 
3,4-Dimethoxy-5-methyl-2-(trimethylsilyl)phenyl isopropylcarbamate (S5).  Note:  Vigorous 
stirring was required throughout the course of the reaction due to the formation of insoluble tri-
flate salts.  Carbamate S4 (17.30 g, 68.2 mmol, 1 equiv) was dissolved in Et2O (340 mL, 0.2 M) 
N,N,Nʹ,Nʹ-tetramethylethylenediamine (TMEDA, 11.3 mL, 75.1 mmol, 1.1 equiv) was added and 
the solution was cooled to 0 ºC before tert-butyldimethylsilyl triflate (TBSOTf, 17.25 mL, 75.1 
mmol, 1.1 equiv) was added in a slow stream.  The solution was stirred 10 min at 0 ºC, removed 
from the ice bath and stirred at 23 ºC for 30 min.  A second portion of TMEDA (41 mL, 273 
mmol, 4 equiv) was added and the solution was cooled to –78 ºC.  n-Butyllithium (2.4 M, 114 
mL, 274 mmol, 4 equiv) was added in a dropwise fashion through a flame-dried addition funnel 
over the course of 1 h, being sure to not let the temperature rise significantly.  The resulting yel-
low suspension was stirred vigorously for 4 h at –78 ºC, taking care not to let the temperature 
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rise.  Trimethylsilyl chloride (61 mL, 478 mmol, 7 equiv) was then added dropwise via the addi-
tion funnel over the course of 30 min and the suspension was stirred at –78 ºC for 30 min, then 
was removed from the dry ice bath and stirred at 23 ºC for 16 h.  The reaction was quenched by 
the addition of 300 mL aqueous NH4Cl (30 mL saturated solution diluted to 300 mL) through an 
addition funnel, the first 50 mL of which were added dropwise, followed by the addition of the 
remainder in a slow stream.  The aqueous phase was then further acidified by the addition of 
small portions of concentrated HCl until an acidic pH was achieved (~30 mL required).  The lay-
ers were separated and the aqueous phase was extracted twice with Et2O.  The combined organic 
phases were washed with saturated aqueous NH4Cl, dried over MgSO4 and concentrated.  The 
product was purified by column chromatography (20–30% Et2O/hex).  Colorless solid, 20.61 g, 
63.3 mmol, 93% yield.  NMR spectra were identical to the previously reported compound (49). 
1H NMR (300 MHz, CDCl3) δ 6.63 (s, 1H), 4.69 (d, J = 8.1 Hz, 1H), 3.96–3.85 (m, 1H), 3.83 (s, 
3H), 3.76 (s, 3H), 2.23 (s, 3H), 1.24 (s, 3H), 1.22 (s, 3H), 0.30 (s, 9H); 157.9, 13C NMR (126 
MHz, CDCl3) δ 157.9, 154.2, 150.5, 148.5, 134.6, 123.0, 120.1, 60.5, 59.8, 43.5, 23.1, 16.1, 1.3. 
3,4-Dimethoxy-5-methyl-2-(trimethylsilyl)phenyl trifluoromethanesulfonate (14).  Note: 
Arene 14 can be isolated as a colorless oil, but undergoes decomposition and should be used 
within the day of its isolation.  Carbamate S5 (8.08 g, 24.8 mmol, 1 equiv) was dissolved in THF 
(100 mL, 0.25 M) and diethylamine (3.85 mL, 37.2 mmol, 1.5 equiv) was added and the solution 
was cooled to –78 ºC.  n-Butyllithium (2.5 M, 15 mL, 37.5 mmol, 1.5 equiv) was added slowly 
over the course of 15 min.  The solution was stirred at that temperature for 30 min, then removed 
from its bath and stirred at 23 ºC for 30 min.  N-Phenyl triflimide (10.6 g, 29.8 mmol, 1.2 equiv) 
was added in one portion and the solution was stirred 30 min.  A second portion of diethylamine 
(4.6 mL, 44.7 mmol, 1.8 equiv) was added and the solution was stirred 2 h.  The solution was 
filtered through a 1 inch pad of silica gel with 50% Et2O/hex and concentrated.  The product was 
purified by column chromatography (10% Et2O/hex).  Colorless oil, 9.15 g, 24.6 mmol, 99% 
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yield.  NMR spectra were identical to the previously reported compound (49).  1H NMR (400 
MHz, CDCl3) δ 6.87 (s, 1H), 3.87 (s, 3H), 3.78 (s, 3H), 2.28 (d, J = 0.7 Hz, 3H), 0.38 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ 158.5, 150.4, 149.0, 135.6, 124.2, 118.7 (q, J = 320.6 Hz), 117.7, 
60.6, 59.8, 16.3, 1.2; 19F NMR (282 MHz, CDCl3) δ -73.1 (s, 3F).  
7,8-Dimethoxy-1,6-dimethyl-3-hydroxyisoquinoline (16).  Cesium fluoride (204 mg, 1.34 
mmol, 2.5 equiv) was dissolved in acetonitrile (5.4 mL, 0.1 M) in a 20 mL microwave vial and 
water (9.7 µL, 0.537 mmol, 1.0 equiv) and methyl acetoacetate (58 µL, 0.537 mmol, 1.0 equiv) 
were added.  Aryne precursor 14 (250 mg, 0.671 mmol, 1.25 equiv) was added neat via syringe, 
and the vial was placed in a preheated 80 ºC oil bath.  After 2 h, TLC revealed complete con-
sumption of 14, so NH4OH (28–30%, 5.4 mL) was added in one portion.  The vial was moved to 
a preheated 60 ºC oil bath and stirred for 8 h.  The solution was poured into brine inside a separa-
tory funnel and the solution was extracted with EtOAc (2x 30 mL).  The aqueous phase was 
brought to pH 7 by the addition of concentrated HCl and was extracted with EtOAc (2x 30 mL). 
The aqueous phase was discarded.  The organic phase was then extracted with 2M HCl (5x 20 
mL).  The organic phase was checked by LCMS to confirm that all of product 16 had transferred 
to the aqueous phase and was subsequently discarded.  The aqueous phase was then brought back 
to pH 7 by the addition of 100 mL 2M NaOH and was extracted with EtOAc (5x 20 mL).  The 
combined organic phases were washed with brine, dried over Na2SO4 and concentrated, provid-
ing the product.  Yellow solid, 56.9 mg, 0.243 mmol, 45% yield.  1H NMR (300 MHz, CDCl3) δ 
6.92 (d, J = 0.7 Hz, 1H), 6.51 (s, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 3.03 (d, J = 0.7 Hz, 3H), 2.28 
(d, J = 1.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 161.8, 149.5, 145.9, 142.6, 140.4, 121.4, 
113.1, 104.8, 60.5, 60.2, 21.1, 17.3; IR (thin film, NaCl):  3327.0, 2937.6, 2608.7, 1651.7, 
1455.4, 1324.2, 1226.8, 1177.9, 1147.2, 1089.5, 1062.3, 1034.8, 1000.5, 960.0, 937.7, 892.4, 
861.7, 813.2, 724.1, 682.8, 662.3; HRMS (ESI-TOF) calc’d for [M+] C13H15NO3 = 233.1052, 
found 233.1057. Note:  When performed on multi-gram scale, this reaction proved highly vari-
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able due to unknown factors.  Yields typically dropped into the 20–30% range.  We have there-
fore developed the two-step procedure below that requires extensive column chromatography and 
generates significantly more organic waste, but that does provide hydroxyisoquinoline 16 in 
higher overall yield. 
Methyl 2-(2-acetyl-3,4-dimethoxy-5-methylphenyl)acetate (S18).  Anhydrous potassium fluo-
ride (7.0 g, 120.5 mmol, 3.3 equiv) and 18-crown-6 (31.0 g, 117.3 mmol, 3.2 equiv) were 
weighed into a flame-dried 1L recovery flask inside a nitrogen-filled glovebox to minimize ex-
posure to atmospheric water.  The flask was removed from the glovebox, anhydrous THF (370 
mL, 0.1 M in 14) was added and the resulting slurry was heated to 50 °C in an oil bath.  Aryne 
precursor 14 (13.67 g, 36.7 mmol, 1.0 equiv) was dissolved in anhydrous THF (30 mL) and 
added to the warm fluoride solution in a slow, dropwise fashion via cannula over 1 h, followed 
by a 10 mL rinse of the flask and cannula, added rapidly.  After stirring 1 h at 50 °C, TLC re-
vealed complete consumption of 14 and the appearance of at least five new products (the product 
has an Rf = 0.35 in 20% EtOAc/hex, major middle spot).  The crude reaction was filtered through 
a 1” pad of SiO2 using 1L of 30% EtOAc/hex and the filtrate was concentrated.  The product was 
purified by column chromatography [4x10” SiO2, 2L 5% EtOAc/hex (collected in Erlenmeyer 
flasks)–1.5L 10%–1.5L 20%–1L 30%–600 mL 50% EtOAc/hex].  The product could not be 
completely purified from the reaction mixture, but using the above conditions S18 could be ob-
tained in roughly 80% purity as estimated by 1H NMR.  Colorless oil, 6.70 g isolated, ~5.36 g 
S18 adjusted for purity, ~20.1 mmol, ~55% yield.  NMR spectra were identical to the previously 
reported compound (50).  Because of the low purity, only 1H NMR spectra were recorded for this 
compound.  1H NMR (500 MHz, CDCl3) δ 6.78 (q, J = 0.7 Hz, 1H), 3.87 (s, 3H), 3.82 (s, 4H), 
3.68 (s, 3H), 3.62 (s, 2H), 2.55 (s, 3H), 2.24 (d, J = 0.7 Hz, 3H). 
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7,8-Dimethoxy-1,6-dimethyl-3-hydroxyisoquinoline (16).  In a 250 mL flask equipped with a 
Kontes valve, arene S18 was dissolved in MeCN (15 mL) and NH4OH (28–30%, 30 mL), the 
flask was sealed to prevent loss of gaseous ammonia and was placed in a preheated 60 °C oil 
bath.  Within 1 h yellow 16 began to precipitate from the reaction solution.  After stirring at 60 
ºC for 18 h, the flask was cooled to room temperature, then placed in a –25 °C freezer for 3 h, 
after which time the suspension was filtered.  The yellow filter cake was washed with cold (–25 
°C) MeCN until the filtrate was no longer yellow.  The filter cake was allowed to dry on the filter 
paper for 15 min, then was transferred to a vial and dried at high vacuum for 24 h to provide the 
analytically pure product.  Yellow solid, 3.61 g, 15.5 mmol, 77% yield.  1H NMR (300 MHz, 
CDCl3) δ 6.92 (d, J = 0.7 Hz, 1H), 6.51 (s, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 3.03 (d, J = 0.7 Hz, 
3H), 2.28 (d, J = 1.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 161.8, 149.5, 145.9, 142.6, 140.4, 
121.4, 113.1, 104.8, 60.5, 60.2, 21.1, 17.3; IR (thin film, NaCl):  3327.0, 2937.6, 2608.7, 1651.7, 
1455.4, 1324.2, 1226.8, 1177.9, 1147.2, 1089.5, 1062.3, 1034.8, 1000.5, 960.0, 937.7, 892.4, 
861.7, 813.2, 724.1, 682.8, 662.3; HRMS (ESI-TOF) calc’d for [M+] C13H15NO3 = 233.1052, 
found 233.1057. 
   
7,8-Dimethoxy-1,6-dimethyl-3-(trifluoromethanesulfonyloxy)isoquinoline (10).  Hydroxy-
isoquinoline 16 (2.60 g, 11.1 mmol, 1 equiv) was dissolved in CH2Cl2 (70 mL, 0.16 M) and pyri-
dine (11.4 mL, 140.6 mmol, 12.7 equiv) was added and the solution was cooled to 0 ºC.  Trifluo-
romethanesulfonic anhydride (Tf2O, 3.00 mL, 17.8 mmol, 1.6 equiv) was added dropwise, caus-
ing the yellow solution to turn dark red.  After 30 min TLC (10% EtOAc/hex) revealed complete 
conversion, so the reaction was quenched by the addition of saturated aqueous NaHCO3 (70 mL). 
(94% yield)
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The solution was stirred vigorously until bubbling ceased, at which time the layers were separat-
ed.  The organic phase was extracted with CH2Cl2 and the combined organic phases were dried 
over Na2SO4 and concentrated.  The product was purified by column chromatography (10% 
Et2O/hex).  Yellow oil, 3.82 g, 10.5 mmol, 94% yield.  1H NMR (400 MHz, CDCl3) δ 7.39 (d, J 
= 1.0 Hz, 1H), 7.21 (s, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.07 (d, J = 0.7 Hz, 3H), 2.44 (d, J = 1.0 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 158.6, 151.0, 150.5, 149.9, 139.2, 136.8, 123.6, 122.9, 
118.8 (q, J = 320.5 Hz), 107.6, 60.8, 60.2, 26.7, 17.0; 19F NMR (282 MHz, CDCl3) δ -72.99; IR 
(thin film, NaCl):  3436.0, 2939.4, 1605.5, 1553.6, 1493.7, 1415.9, 1381.0, 1351.9, 1332.9, 
1248.8, 1209.3, 1133.6, 1097.0, 1059.9, 1009.8, 983.4, 966.2, 940.7, 892.0, 834.7, 768.1, 695.0, 
649.3, 608.2; HRMS (ESI-TOF) calc’d for [M+] C14H14F3NO5S = 365.0545, found 365.0547. 
Fagnou Cross-Coupling Reaction. 
3-(((tert-butyldimethylsilyl)oxy)methyl)-5,7,7',8'-tetramethoxy-1',6,6'-trimethyl-[1,3'-biiso-
quinoline] 2-oxide (18).  Palladium acetate (347 mg, 1.54 mmol, 0.20 equiv), di-tert-butyl 
(methyl)phosphonium tetrafluoroborate (957 mg, 3.86 mmol, 0.50 equiv), and cesium carbonate 
(1.26 g, 3.41 mmol, 0.50 equiv) were weighed into a 100 mL pear-shaped flask and brought into 
a nitrogen-filled glovebox and cesium pivalate (CsOPiv, 722 mg, 3.09 mmol, 0.40 equiv) was 
added to the flask.  In the glovebox, degassed toluene (80 mL) was added, the flask was sealed 
with a rubber septum and removed from the glovebox, to be placed in a 60 ºC preheated oil bath, 
where it was stirred for 30 min and allowed to cool to room temperature.  In the meantime, N-
oxide 9 (8.42 g, 23.1 mmol, 3 equiv) and cesium carbonate (7.54 g, 23.1 mmol, 3 equiv) were 
weighed into a 250 mL sealable flask equipped with a Kontes valve, to which 50 mL toluene was 
added, and this suspension was sparge-degassed with nitrogen for 10 min.  Isoquinoline triflate 
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10 (2.77 g, 6.82 mmol, 1.00 equiv) was dissolved in 10 mL toluene, which was sparge-degassed 
with nitrogen for 10 min.  The solution of isoquinoline triflate 10 was then added via cannula to 
the cooled catalyst solution, rinsing the flask with 5 mL degassed toluene.  The catalyst/triflate 
solution was then added via cannula to the 250 mL sealable flask, rinsing with 10 mL degassed 
toluene.  The flask was sealed and placed in a 130 ºC preheated oil bath for 4.5 h.  The flask was 
then allowed to cool to room temperature and Celite (10 g) was added.  This suspension was then 
filtered through a 1 inch pad of Celite that was topped with sand, rinsing with CH2Cl2 and ace-
tone (500 mL each).  The solution was concentrated, providing the crude product.  1H NMR of 
the crude reaction mixture showed a 2:1 mixture of bis-isoquinoline 18 and N-oxide 9 at this 
point, indicating complete conversion to product.  The product was purified by column chro-
matography (10–20% EtOAc/hex, then 20–50–100% EtOAc/hex + 1% NEt3, then 10–20% 
MeOH/EtOAc + 1% NEt3.  bis-Isoquinoline 18 elutes during the 50–100% EtOAc/hex portion, 
and remaining N-oxide 9 elutes during the 10–20% MeOH/EtOAc portion).  Colorless foam, 
3.88 g, 6.70 mmol, 98% yield.  An analogous coupling performed with 2.39 g isoquinoline tri-
flate 10 provided 3.30 g of product (87% yield), together providing 7.18 g bis-isoquinoline 18 in 
93% average yield.  1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 0.9 Hz, 1H), 7.81 (s, 1H), 7.42 
(d, J = 1.1 Hz, 1H), 6.60 (s, 1H), 5.06 (d, J = 1.4 Hz, 2H), 4.01 (s, 3H), 3.97 (s, 3H), 3.90 (s, 3H), 
3.65 (s, 3H), 3.17 (s, 3H), 2.45 (d, J = 0.9 Hz, 3H), 2.28 (s, 3H), 1.03 (s, 9H), 0.17 (s, 6H); 13C 
NMR (101 MHz, CDCl3) δ 158.9, 157.8, 153.8, 151.3, 149.6, 146.0, 143.7, 142.0, 137.6, 134.8, 
128.2, 124.3, 122.7, 122.5, 121.5, 120.4, 114.5, 98.6, 61.8, 60.9, 60.4, 60.3, 55.7, 27.2, 26.1, 
18.5, 17.1, 9.7, –5.2; IR (thin film, NaCl):  3417.9, 2954.4, 2856.9, 1614.6, 1567.0, 1463.4, 
1392.7, 1328.6, 1255.0, 1213.2, 1189.5, 1139.2, 1117.7, 1089.2, 1057.0, 1008.0, 961.2, 936.5, 
897.0, 839.1, 815.5, 778.4, 734.4, 701.8, 634.2; HRMS (ESI-TOF) calc’d for [M+] C32H42N2O6Si 
= 578.2812, found 578.2796. 
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First-Generation Synthesis of bis-Isoquinoline 8. 
3-(((Tert-butyldimethylsilyl)oxy)methyl)-5,7,7’,8'-tetramethoxy-1',6,6'-trimethyl-1,3'-biiso-
quinoline (S8).  Bis-isoquinoline-N-oxide 18 (6.16 g, 10.6 mmol, 1.00 equiv) was dissolved in 
CH2Cl2 (210 mL, 0.05 M) and the solution was cooled to 0 ºC.  Neat phosphorus trichloride 
(1.86 mL, 21.3 mmol, 2.00 equiv) was added at a dropwise pace over 5 minutes, causing the so-
lution to immediately turn dark purple.  After 30 min, TLC revealed complete conversion to the 
product, so the reaction was quenched with saturated aqueous K2CO3 and diluted with water. 
The layers were separated and the aqueous phase was extracted with EtOAc.  The combined or-
ganic phases were dried over Na2SO4 and concentrated (note:  a brine wash caused a significant 
emulsion regardless of extraction solvent, and was avoided).  The product was purified by col-
umn chromatography (10% EtOAc/hex + 1% NEt3).  Yellow solid, 5.44 g, 9.67 mmol, 91% 
yield).  1H NMR (400 MHz, CDCl3) δ 8.03 (q, J = 1.1 Hz, 1H), 8.00 (s, 1H), 7.87 (s, 1H), 7.47 
(d, J = 0.6 Hz, 1H), 5.08 (d, J = 1.2 Hz, 2H), 4.02 (s, 3H), 3.98 (s, 3H), 3.92 (s, 3H), 3.85 (s, 3H), 
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3.21 (s, 3H), 2.47 (d, J = 0.9 Hz, 3H), 2.36 (s, 3H), 1.04 (s, 9H), 0.18 (s, 6H); 13C NMR (101 
MHz, CDCl3) δ 157.4, 156.1, 155.5, 153.6, 152.2, 150.9, 150.6, 149.6, 137.4, 135.5, 129.0, 
125.9, 124.6, 124.2, 122.1, 119.8, 110.4, 101.2, 66.4, 61.6, 60.9, 60.4, 55.6, 27.2, 26.2, 18.6, 
17.1, 9.8, –5.2. 
(5,7,7’,8’-Tetramethoxy-1',6,6'-trimethyl-[1,3'-biisoquinolin]-3-yl)methanol (S6).  Bis-iso-
quinoline S8 (5.44 g, 9.7 mmol, 1.00 equiv) was dissolved in acetic acid (40 mL, 0.25 M) and 
solid potassium fluoride (2.81 g, 48.0 mmol, 5.00 equiv) was added in one portion.  The solution 
was stirred 30 min at room temperature, at which time LCMS showed complete conversion to 
the product.  The solution was diluted with CH2Cl2 and ice and the solution was stirred vigorous-
ly as a solution of sodium hydroxide (25 g, 0.625 mol, 0.9 equiv relative to 40 mL AcOH) in 70 
mL water was added slowly.  The rest of the acetic acid was quenched by the addition of saturat-
ed aqueous K2CO3.  The layers were separated and the aqueous phase was extracted with 
CH2Cl2.  The combined organic phases were washed with brine, dried over Na2SO4 and concen-
trated.  The product was purified by column chromatography (1–2–3–4–5% MeOH/CH2Cl2 + 
1% NEt3).  Colorless solid, 4.17 g, 9.31 mmol, 96% yield.  1H NMR (400 MHz, CDCl3) δ 8.09 
(s, 1H), 8.03 (s, 1H), 7.79 (d, J = 0.9 Hz, 1H), 7.49 (d, J = 1.1 Hz, 1H), 4.94 (s, 2H), 4.03 (s, 3H), 
3.97 (s, 3H), 3.89 (s, 3H), 3.87 (s, 3H), 3.22 (s, 3H), 2.47 (d, J = 1.0 Hz, 3H), 2.35 (s, 4H); 13C 
NMR (101 MHz, CDCl3) δ 157.8, 156.0, 155.2, 153.5, 151.1, 150.3, 149.7, 149.6, 137.6, 135.4, 
129.0, 126.2, 124.7, 124.6, 122.2, 119.9, 111.3, 101.3, 65.0, 61.7, 60.9, 60.3, 55.6, 27.2, 17.1, 
9.9; IR (thin film, NaCl):  3352.3, 3128.9, 2936.6, 2855.0, 1620.4, 1594.1, 1556.8, 1484.4, 
1462.2, 1454.9, 1416.4, 1392.3, 1355.0, 1331.4, 1303.1, 1243.0, 1218.0, 1195.9, 1133.0, 1117.1, 
1090.7, 1059.8, 1008.2, 963.5, 906.0, 884.5, 841.2, 795.7, 732.6, 645.8; HRMS (ESI-TOF) 
calc’d for [M+] C26H28N2O5 = 448.1998, found 448.1992. 
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Methyl 5,7,7’,8’-tetramethoxy-1',6,6'-trimethyl-[1,3'-biisoquinoline]-3-carboxylate (S7). 
bis-Isoquinoline S6 (1.50 g, 3.34 mmol, 1.00 equiv) and silver(I) oxide (3.88 g, 16.7 mmol, 5.00 
equiv) were slurried in MeOH (35 mL, 0.1 M).  After 30 min, the solution appeared to be fully 
homogeneous and deep red in color.  After 4 h, LCMS showed full conversion to a mixture of 
methyl ester S7 and the corresponding carboxylic acid.  Thionyl chloride (1.21 mL, 16.7 mmol, 
5.00 equiv) was added through the top of a reflux condenser, and following the complete addi-
tion the solution was heated to reflux  After 1.5 h, LCMS showed complete conversion to methyl 
ester S7.  The solution was cooled to room temperature and celite was added, and the solution 
was filtered through more celite, rinsing with EtOAc.  The solution was concentrated, then redis-
solved in CH2Cl2 and washed with dilute aqueous K2CO3 and brine.  The layers were separated 
and the aqueous phase was extracted with CH2Cl2.  The combined organic phases were washed 
with brine, dried over Na2SO4 and concentrated.  The product was purified by column chro-
matography (25% EtOAc/hex + 1% NEt3).  White solid, 1.40 g, 2.94 mmol, 88% yield.      1H 
NMR (400 MHz, CDCl3) δ 8.75 (d, J = 0.9 Hz, 1H), 8.19 (s, 1H), 8.13 (s, 1H), 7.52 (d, J = 1.1 
Hz, 1H), 4.05 (s, 3H), 4.01 (s, 3H), 3.97 (s, 3H), 3.94 (s, 3H), 3.90 (s, 3H), 3.20 (s, 3H), 2.46 (d, 
J = 1.0 Hz, 3H), 2.36 (s, 3H); 1H NMR (400 MHz, CDCl3) δ 167.0, 160.0, 156.0, 155.8, 154.9, 
151.1, 149.9, 149.5, 139.0, 137.5, 135.6, 128.6, 128.0, 125.0, 124.7, 122.3, 120.5, 118.6, 101.9, 
62.3, 60.9, 60.3, 55.8, 52.8, 27.1, 17.1, 9.9; IR (thin film, NaCl):  3443.0, 2948.7, 1714.1, 
1614.7, 1454.4, 1407.2, 1384.3, 1330.3, 1304.7, 1270.1, 1226.4, 1136.9, 1088.6, 1057.2, 1008.0, 
870.5, 786.0, 733.2;  HRMS (ESI-TOF) calc’d for [M+] C27H28N2O6 = 476.1947, found 
476.1952. 
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Methyl 1’-formyl-5,7,7',8'-tetramethoxy-6,6'-dimethyl-[1,3'-biisoquinoline]-3-carboxylate 
(S8) and methyl 1’-(hydroxy(methoxy)methyl)-5,7,7',8'-tetramethoxy-6,6'-dimethyl-[1,3'-
biisoquinoline]-3-carboxylate (S9) and methyl 1’-(hydroxy(methoxy)methyl)-5,7,7',8'-
tetramethoxy-6,6'-dimethyl-[1,3'-biisoquinoline]-3-carboxylate (S10).  bis-Isoquinoline S7 
(1.40 g, 2.94 mmol, 1.00 equiv) and selenium dioxide (652 mg, 5.88 mmol, 2.00 equiv) was slur-
ried in dioxane and the flask was fitted with a reflux condenser.  The flask was vacuum purged/
refilled with N2 five times, then heated to reflux.  At about 80 ºC the solution became fully ho-
mogeneous.  After 1 h at reflux, the flask was cooled to room temperature and LCMS showed 
full conversion to aldehyde S9.  Celite was added to the crude reaction and the resulting slurry 
was filtered through more celite, rinsing with EtOAc.  SiO2 was added to the filtrate and the so-
lution was concentrated.  Due to the insolubility of the products, a mixture of MeOH and CH2Cl2 
was required during purification by column chromatography (10% MeOH/DCM + 1% NEt3). 
During this process, the highly electrophilic aldehyde moiety is converted to the hemiacetal in a 
thermodynamic 85:15 mixture favoring the hemiacetal.  The two products can neither be inter-
converted nor separated, and as such was characterized as a mixture.  White solid, total mass = 
1.47 g, 85:15 molar ratio of S10:S9 by 1H NMR, corresponding to 1.25 g hemiacetal S10 (2.39 
mmol, 82% yield) and 220 mg S9 (0.45 mmol, 15% yield), 2.84 mmol total, 97% combined 
yield.  Aldehyde S9:  1H NMR (400 MHz, CDCl3) δ 10.92 (s, 1H), 8.78 (s, 1H), 8.72 (s, 1H), 
8.56 (s, 1H), 7.68 (d, J = 1.2 Hz, 1H), 4.07 (s, 3H), 4.04 (s, 3H), 4.02 (s, 3H), 3.95 (s, 3H), 3.70 
(s, 3H), 2.51 (d, J = 1.0 Hz, 3H), 2.37 (s, 3H);  13C NMR (101 MHz, CDCl3) δ 193.4, 160.6, 
154.8, 154.1, 151.8, 151.3, 151.0, 147.1, 139.2, 135.8, 128.7, 128.1, 125.3, 125.0, 124.1, 121.6, 
119.1, 102.0, 67.2, 60.7, 60.6, 56.3, 46.1, 17.4.  Hemiacetal S10:  1H NMR (400 MHz, CDCl3) δ 
8.78 (d, J = 0.8 Hz, 1H), 8.44 (s, 1H), 7.97 (s, 1H), 7.61 (d, J = 1.1 Hz, 1H), 6.52 (d, J = 10.6 Hz, 
1H), 6.41 (d, J = 10.6 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 3.98 (s, 3H), 3.98 (s, 3H), 3.92 (s, 3H), 
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3.63 (s, 3H), 2.48 (d, J = 1.0 Hz, 3H), 2.37 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 166.8, 160.3, 
155.2, 154.9, 152.9, 151.5, 148.6, 148.2, 138.9, 138.6, 136.5, 128.5, 127.9, 125.2, 124.9, 123.4, 
120.1, 118.9, 101.5, 95.2, 62.3, 60.8, 60.3, 56.0, 55.2, 52.8, 17.3, 10.0.  IR (thin film, NaCl): 
3436.7, 2948.9, 2846.9, 1737.7, 1711.2, 1619.9, 1462.1, 1386.6, 1304.0, 1272.2, 1228.6, 1136.2, 
1086.2, 1001.8, 900.5, 734.1; HRMS (ESI-TOF) for aldehyde S9 calc’d for [M+] C27H26N2O7 = 
490.1740, found 490.1742; HRMS (ESI-TOF) for hemiacetal S10 calc’d for [M+] C28H30N2O8 = 
522.2002, found 522.2005.
Methyl 1'-(hydroxymethyl)-5,7,7',8'-tetramethoxy-6,6'-dimethyl-[1,3'-biisoquinoline]-3-
carboxylate dichloromethane solvate (8•CH2Cl2).  Note:  Aldehyde S7 and hemiacetal S9 ap-
pear to be in thermal equilibrium at 23 ºC in a 4:1 v/v mixture of CH2Cl2:MeOH in a 1:3 ratio of 
S9:S10.  When excess NaBH4 is utilized, competitive reduction of the methyl ester was observed; 
however, when NaBH4 was employed in substoichiometric fashion, selective reduction of the 
aldehyde was observed.  Presumably the reaction proceeds to completion as a manifestation of 
Le Châtelier’s principle.  A mixture of bis-isoquinolines S9 and S10 (2.84 mmol in total, 1.00 
equiv) was dissolved in CH2Cl2 (24 mL) and MeOH (6 mL, 0.1 M) and sodium borohydride 
(36.0 mg, 0.946 mmol, 0.33 equiv) was added.  Gas evolution observed for ~1 minute, then 
stopped.  5 minutes after the addition of sodium borohydride LCMS showed complete and selec-
tive reduction to desired product 8.  The reaction was quenched by the addition of citric acid 
monohydrate (594 mg, 2.84 mmol, 1.00 equiv) and water and the solution was stirred at 1500 
rpm for 10 min, then is basified by the addition of saturated aqueous NaHCO3.  The layers were 
separated and the aqueous phase was extracted with CH2Cl2.  The combined organic phases were 
dried over Na2SO4 and concentrated.  The product was purified by column chromatography us-
ing a 1:1 mixture of CH2Cl2:EtOAc as the polar solvent (20–30–40–50–60–100% polar solvent/
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hex + 1% NEt3).  Colorless solid, 1.55 g, 2.68 mmol, 98% yield.  Note:  A stoichiometric amount 
of dichloromethane could not be removed from the product despite extensive time on high vacu-
um (10 mTorr), leading to the conclusion that the product is isolated as a stoichiometric di-
chloromethane monosolvate.  1H NMR (400 MHz, CDCl3) δ 8.79 (d, J = 0.8 Hz, 1H), 8.30 (s, 
1H), 7.90 (s, 1H), 7.59 (d, J = 0.5 Hz, 1H), 5.55 (t, J = 3.5 Hz, 1H), 5.39 (d, J = 3.5 Hz, 2H), 
5.30 [s, 2H (CH2Cl2)], 4.06 (s, 3H), 4.06 (s, 3H), 3.99 (s, 3H), 3.96 (s, 3H), 3.90 (s, 3H), 2.49 (d, 
J = 0.9 Hz, 3H), 2.38 (s, 3H); 1H NMR (400 MHz, CDCl3) δ 166.9, 160.2, 155.8, 155.6, 155.0, 
151.1, 149.1, 148.5, 139.0, 138.4, 135.5, 128.5, 127.9, 125.3, 124.8, 121.6, 120.3, 118.8, 101.3, 
64.7, 62.4, 60.9, 60.3, 56.1, 53.4, 52.9, 17.2, 10.0; IR (thin film, NaCl): 3364.8, 3130.4, 2930.2, 
2856.2, 1690.6, 1620.8, 1594.3, 1556.6, 1462.3, 1413.2, 1391.8, 1356.6, 1330.7, 1302.1, 1258.7, 
1196.3, 1130.7, 1088.7, 1058.5, 1010.1, 964.2, 885.9, 838.1, 801.9, 777.4, 734.0; HRMS (ESI-
TOF) calc’d for [M+] C27H28N2O7 = 492.1897, found 492.1894.
Second-Generation Synthesis of bis-Isoquinoline 8. 
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1'-(acetoxymethyl)-3-(((tert-butyldimethylsilyl)oxy)methyl)-5,7,7',8'-tetramethoxy-6,6'-di-
methyl-[1,3'-biisoquinoline] 2-oxide (20). Note:  Addition of the catalyst in a single portion re-
sulted in rapid over-oxidation, but addition in 3 portions, at least 20 minutes apart resulted in 
clean conversion.  Furthermore, bis-N-oxide 19 was not stable to Na2SO4, MgSO4, or SiO2, and 
as such it was neither dried nor purified by column chromatography, but the clean reaction pro-
file did not necessitate purification.  Bis-isoquinoline-N-oxide 18 (150 mg, 0.259 mmol, 1 equiv) 
and methyl trioxorhenium (1.3 mg, 0.0052 mmol, 0.02 equiv) were dissolved in CH2Cl2 (2.6 mL, 
0.1 M) and 35% aqueous hydrogen peroxide (40 µL, 0.454 mmol, 1.75 equiv) was added.  The 
solution was stirred at 1300 rpm for 30 min, at which point a second portion of MeReO3 (1.3 mg, 
0.0052 mmol, 0.02 equiv) was added.  After 30 min, a third and final portion of MeReO3 (1.3 
mg, 0.0052 mmol, 0.02 equiv) was added.  After a further 30 min, LCMS showed complete con-
sumption of the bis-isoquinoline-N-oxide, so acetic anhydride (0.122 ml, 1.30 mmol, 5 equiv) 
was then added and the reaction mixture was stirred at 23 °C. After 12 hours, LCMS showed 
complete consumption of the bis-N-oxide. The reaction was quenched with water and basified 
with aqueous K2CO3.  The layers were separated and the aqueous phase was extracted with 
CH2Cl2.  The combined organic layers were dried over Na2SO4, filtered, concentrated, and 
azeotroped with benzene twice.  The crude product was purified by column chromatography 
(35% EtOAc/hex + 1% NEt3). Yellow foam, 102.0 mg, 0.160 mmol, 62% yield. 1H NMR (400 
MHz, CDCl3) δ 8.15 (s, 1H), 8.05 (s, 1H), 7.49 (s, 1H), 6.64 (s, 1H), 5.85 (s, 2H), 5.05 (s, 2H), 
4.04 (s, 3H), 3.96 (s, 3H), 3.92 (s, 3H), 3.73 (s, 3H), 2.46 (s, 3H), 2.29 (s, 3H), 1.99 (s, 3H), 1.04 
(s, 9H), 0.18 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 171.2, 159.1, 153.2, 145.8, 138.2, 134.9, 
128.3, 124.4, 123.8, 122.9, 114.7, 98.8, 68.1, 61.8, 60.9, 60.4, 60.2, 55.8, 26.1, 21.1, 18.5, 17.1, 
9.8, –5.2.  IR (thin film, NaCl):  2931.8, 2856.3, 1742.2, 1613.9, 1556.5, 1462.7, 1454.2, 1359.3, 
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1316.3, 1236.4, 1137.2, 1090.0, 1006.4, 896.6, 838.7, 754.5; HRMS (ESI-TOF) calc’d for 
[M+H]+ C34H45N2O8Si = 637.2940, found 637.2944. 
(3-(hydroxymethyl)-5,7,7',8'-tetramethoxy-6,6'-dimethyl-[1,3'-biisoquinolin]-1'-yl)methyl 
acetate (21). To a solution of bis-isoquinoline-N-oxide 21 (99.0 mg, 0.155 mmol, 1 equiv) in 
acetic acid (1.6 mL), Fe powder (86.8 mg, 1.55 mmol, 10 equiv) was added at 23 °C. The reac-
tion mixture was stirred at 50 °C for 3 hours, at which point the LCMS showed complete con-
sumption of the starting material. The reaction mixture was then cooled to room temperature and 
KF (90.1 mg, 1.55 mmol, 10 equiv) was added. After 12 hours, LCMS showed complete con-
sumption of the TBS-protected alcohol intermediate, so the reaction was diluted with CH2Cl2 and 
washed with aqueous K2CO3. The aqueous layer was separated and extracted with EtOAc twice. 
The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The 
crude was purified by column chromatography (50% EtOAc/CH2Cl2 + 1% Et3N). Pale yellow 
solid, 48.1 mg, 0.095 mmol, 61% yield. 1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.85 (s, 1H), 
7.74 (d, J = 0.9 Hz, 1H), 7.47 (d, J = 1.1 Hz, 1H), 5.84 (s, 2H), 4.87 (d, J = 0.9 Hz, 2H), 3.99 (s, 
3H), 3.88 (s, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 2.41 (d, J = 1.0 Hz, 3H), 2.29 (s, 3H), 1.98 (s, 3H); 
13C NMR (101 MHz, CDCl3) δ 171.2, 157.9, 155.1, 153.5, 151.6, 151.0, 150.5, 149.5, 148.6, 
138.1, 135.7, 129.0, 126.3, 124.8, 124.6, 121.5, 121.1, 111.5, 101.3, 68.3, 64.9, 61.8, 60.9, 60.2, 
55.8, 21.2, 17.1, 10.0; IR (thin film, NaCl):  3417.7, 2939.0, 1738.2, 1594.6, 1556.7, 1454.6, 
1417.6, 1303.0, 1237.5, 1130.7, 1091.1, 1006.3, 888.4, 754.5; HRMS (ESI-TOF) calc’d for 
[M+H]+ C28H31N2O7 = 507.2126, found 507.2130. 
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Methyl 1’-(hydroxymethyl)-5,7,7',8'-tetramethoxy-6,6'-dimethyl-[1,3'-biisoquinoline]-3-
carboxylate (8). Alcohol 21 (29.5 mg, 0.058 mmol, 1 equiv), TEMPO (4.5 mg, 0.029 mmol, 0.5 
equiv), N-hydroxysuccinimide (7.4 mg, 0.064 mmol, 1.1 equiv), and (diacetoxyiodo)benzene 
(75.0 mg, 0.233 mmol, 4 equiv) were dissolved in CH2Cl2 (1.2 mL, 0.05 M) and stirred at room 
temperature. After 3 hours, LCMS showed complete consumption of the alcohol.  Methanol (1.2 
mL) and p-toluenesulfonic acid monohydrate (110.7 mg, 0.582 mmol, 10 equiv) were added and 
the reaction heated at reflux for 5 hours. The solution was concentrated, then redissolved in 
CH2Cl2 and was washed with dilute aqueous K2CO3 and brine.  The layers were separated and 
the aqueous phase was extracted with CH2Cl2. The combined organic phases were dried over 
Na2SO4 and concentrated.  The product was purified by column chromatography using a 1:1 
mixture of CH2Cl2:EtOAc as the polar solvent (20–30–40–50–60–100% polar solvent/hex + 1% 
NEt3).  Pale yellow solid, 18.6 mg, 0.038 mmol, 65% yield. 1H NMR (400 MHz, CDCl3) δ 8.79 
(d, J = 0.8 Hz, 1H), 8.30 (s, 1H), 7.90 (s, 1H), 7.59 (d, J = 0.5 Hz, 1H), 5.55 (t, J = 3.5 Hz, 1H), 
5.39 (d, J = 3.5 Hz, 2H), 4.06 (s, 3H), 4.06 (s, 3H), 3.99 (s, 3H), 3.96 (s, 3H), 3.90 (s, 3H), 2.49 
(d, J = 0.9 Hz, 3H), 2.38 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 166.9, 160.2, 155.8, 155.6, 
155.0, 151.1, 149.1, 148.5, 139.0, 138.4, 135.5, 128.5, 127.9, 125.3, 124.8, 121.6, 120.3, 118.8, 
101.3, 64.7, 62.4, 60.9, 60.3, 56.1, 53.4, 52.9, 17.2, 10.0; IR (thin film, NaCl): 3364.8, 3130.4, 
2930.2, 2856.2, 1690.6, 1620.8, 1594.3, 1556.6, 1462.3, 1413.2, 1391.8, 1356.6, 1330.7, 1302.1, 
1258.7, 1196.3, 1130.7, 1088.7, 1058.5, 1010.1, 964.2, 885.9, 838.1, 801.9, 777.4, 734.0; HRMS 
(ESI-TOF) calc’d for [M+] C27H28N2O7 = 492.1897, found 492.1894. 
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Asymmetric Hydrogenation of bis-Isoquinoline 8. 
(6S,9R,14aS,15R)-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12-dimethyl-5,6,9,14,14a,15-
hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-7-one (6).  Note:  Due to the 
air-sensitivity of the phosphine ligand and the low-valent iridium complex, the preparation of the 
catalyst and the reaction mixture was performed inside a nitrogen-filled glovebox.  The reaction 
was performed in a 100 mL roundbottom flask with a teflon-coated, egg-shaped stir bar, which 
was placed inside a Parr bomb.  Said bomb was also brought into the glovebox for reaction set-
up, with the exception of the pressure gauge.  A piece of electrical tape was used to seal the 
bomb immediately upon its removal via the large antechamber, and care was taken to minimize 
the time between the removal of the tape and the replacement of the gauge. bis-Isoquinoline 8 
(620 mg, 1.07 mmol, 1 equiv) was weighed in air into a 100 mL roundbottom flask with a teflon-
coated stir bar and the flask was brought into a nitrogen-filled glovebox.  Solid tetra-n-butylam-
monium iodide (238 mg, 0.644 mmol, 0.6 equiv, 3 equiv relative to Ir) was added to the flask. 
[Ir(cod)Cl]2 (72.1 mg, 0.107 mmol, 0.1 equiv, 20 mol% Ir) and BTFM-Xyliphos (a.k.a. SL-J008-
2, 205 mg, 0.225 mmol, 0.21 equiv) were dissolved in 10 mL toluene in a scintillation vial and 
the resulting solution was allowed to stand for 10 min.  28.3 mL of toluene was added to the 
flask containing bis-isoquinoline 8, followed by the addition of 5.4 mL AcOH, resulting in a yel-
low solution of protonated 8.  The iridium-ligand solution was then added to the flask with two 5 
mL rinses, bringing the final volume to 53.7 mL of 9:1 PhMe:AcOH (0.02 M in 8).  The flask 
was sealed with a rubber septum that was then pierced with three 16 gauge (purple) needles, each 
bent at a 90º angle.  The flask was placed inside the bomb, which was then sealed prior to re-
moval from the glovebox via the large antechamber.  At this stage, the tape was removed from 
the top of the bomb and the pressure gauge was quickly screwed in place and tightened.  With 
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200 rpm stirring, the bomb was charged to 10 bar of H2 and slowly released.  This process was 
repeated twice, before charging the bomb to 60 bar of H2, at which time it was placed in a pre-
heated 60 ºC oil bath.  The bath was maintained at this temperature for 18 h, then raised to 80 ºC 
for 24 h.  At this time, the bomb was removed from the oil bath and the hydrogen pressure was 
vented.  The flask was removed from the bomb and the solution was transferred to a 250 mL 
roundbottom flask and basified by the careful addition of saturated aqueous K2CO3 and water 
until pH > 7.  The solution was transferred to a separatory funnel and the layers were separated. 
The aqueous phase was extracted 5x with EtOAc, and the combined organic phases were washed 
twice with water and once with brine, dried over Na2SO4, and concentrated. The product was pu-
rified by column chromatography (15x1”, 1% MeOH/DCM + 1% NEt3).  At this stage, 1H NMR 
determined the purity of the product to be 90% as a brown foam.  469 mg, 422 mg adjusted for 
purity, 0.899 mmol, 83% yield, 88% ee.  Enantiomeric excess was determined by chiral HPLC 
analysis [AD, 20% IPA, 280 nm, 1.0 mL/min:  tR(minor) = 21.6 min, tR(minor) = 26.9 min].  The 
product could then be crystallized to analytical and optical purity (>99% ee) by dissolving the 
brown foam in acetonitrile and allowing the solution to slowly evaporate under a stream of N2. 
The crystals were washed 3x with 500 µL portions of –40 ºC acetonitrile.  The resulting crystals 
were dried in vacuo, providing 203 mg of enantiopure (>99% ee) bis-tetrahydroisoquinoline 6. 
The mother liquor could be purified by preparative SFC (AD-H, 20% IPA/CO2, 210 nm, flow 
rate = 40 mL/min, tR(minor) = 25.0 min, tR(major) = 30.0 min) to provide the remaining material 
in enantiopure fashion.  The crystals isolated above were used to collect the following characteri-
zation data.  1H NMR (500 MHz, CDCl3) δ 6.73 (s, 1H), 6.35 (s, 1H), 5.79 (dd, J = 6.7, 3.8 Hz, 
1H), 4.12 – 4.10 (m, 2H), 3.93 (dt, J = 12.7, 2.9 Hz, 1H), 3.91 (s, 3H), 3.83 (s, 3H), 3.78 (s, 3H), 
3.70 (s, 3H), 3.43 (d, J = 10.6 Hz, 1H), 3.22 – 3.10 (m, 3H), 3.03 (dd, J = 17.2, 6.6 Hz, 1H), 2.74 
(dd, J = 14.5, 2.6 Hz, 1H), 2.67 – 2.60 (m, 1H), 2.25 (s, 3H), 2.15 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 172.9, 157.7, 156.6, 150.0, 149.7, 131.8, 131.2, 130.9, 125.0, 124.4, 119.8, 119.7, 
106.1, 69.0, 61.7, 60.7, 60.4, 60.0, 55.9, 55.0, 54.4, 52.8, 33.2, 30.1, 15.9, 9.2; IR (thin film, 
NaCl):  3301.7, 3052.7, 2940.2, 2859.4, 2835.6, 1621.9, 1614.0, 1486.0, 1463.1, 1455.0, 1410.0, 
1352.8, 1324.3, 1273.8, 1233.6, 1190.8, 1124.8, 1082.0, 1000.5, 957.7, 925.7, 894.4, 849.2, 
S !25
816.5, 788.5, 734.8, 703.2; HRMS (ESI-TOF) calc’d for [M+] C26H32N2O6 = 468.2260, found 
468.2255; [α]D = –56.9º (c = 0.5, CHCl3). 
HPLC Traces of Racemic, Enantioenriched, and Enantiopure 6 
Racemic 6: 
 
Enantioenriched 6: 
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Endgame Synthesis of Jorumycin (1). 
(6S,9R,14aS,15R)-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-trimethyl-5,6,9,14, 
14a,15-hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-7-one (S11).  Enan-
tiopure bis-tetrahydroisoquinoline 6 (120 mg, 0.256 mmol, 1 equiv) was dissolved in 1,2-
dichloroethane (1,2-DCE, 5.1 mL, 0.05 M) and 37% aqueous formaldehyde (35 µL, 0.474 mmol, 
1.85 equiv) was added.  The solution was stirred at 800 rpm for 10 min before sodium triace-
toxyborohydride (307 mg, 1.45 mmol, 5 equiv) was added.  This solution was stirred at 23 ºC for 
15 min, at which time LCMS showed full conversion to the product.  Citric acid monohydrate 
(404 mg, 1.92 mmol, 7.5 equiv) was added to the solution, followed by 20 mL water.  This solu-
tion was stirred for 10 min before the slow addition of saturated aqueous K2CO3 until pH > 7. 
The layers were separated and the aqueous phase was extracted with CH2Cl2.  The combined or-
ganic phases were washed with brine, dried over Na2SO4 and concentrated.  The product was pu-
rified by column chromatography (1% MeOH/DCM + 1% NEt3).  Colorless solid, 123 mg, 0.255 
mmol, quantitative yield.  1H NMR (500 MHz, CDCl3) δ 6.72 (s, 1H), 6.34 (s, 1H), 5.77 (dd, J = 
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6.5, 3.8 Hz, 1H), 4.00 (dt, J = 12.4, 3.0 Hz, 1H), 3.90 (s, 3H), 3.83 (s, 3H), 3.80 – 3.76 (m, 2H), 
3.78 (s, 3H), 3.70 (s, 3H), 3.44 (ddd, J = 8.6, 7.1, 6.0 Hz, 1H), 3.22 – 3.15 (m, 2H), 3.14 (dd, J = 
17.6, 6.5 Hz, 1H), 2.96 (br s, 1H), 2.94 (dd, J = 17.6, 1.2 Hz, 1H), 2.67 (dd, J = 14.5, 2.6 Hz, 
1H), 2.62 – 2.53 (m, 1H), 2.47 (s, 3H), 2.24 (s, 3H), 2.15 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
173.4, 157.4, 156.7, 150.0, 149.7, 131.7, 131.5, 128.8, 125.0, 124.4, 119.7, 119.0, 106.9, 69.1, 
61.4, 60.7, 60.4, 60.3, 60.0, 58.4, 55.9, 52.8, 40.1, 33.0, 24.2, 15.9, 9.1; IR (thin film, NaCl): 
3382.5, 2938.3, 2862.0, 1633.4, 1608.1, 1485.1, 1462.9, 1445.8, 1410.0, 1359.5, 1325.2, 1271.9, 
1232.7, 1189.7, 1123.5, 1080.0, 1015.0, 1001.3, 962.6, 910.0, 847.7, 803.5, 646.4; HRMS (ESI-
TOF) calc’d for [M+] C27H34N2O6 = 482.2417, found 482.2414; [α]D = –76.2º (c = 0.5, CHCl3). 
(6S,9R,14aS,15R)-1,13-dichloro-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-
trimethyl-5,6,9,14,14a,15-hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin- 
7-one (28).  bis-Tetrahydroisoquinoline S11 (179.9 mg, 0.372 mmol, 1.0 equiv) was dissolved in 
HFIP (16.6 mL, 0.02 M after complete addition) and the solution was cooled to 0 ºC.  N-
Chlorosaccharine (170 mg, 0.782 mmol, 2.1 equiv) was dissolved in 2 mL HFIP and this solution 
was added at a slow dropwise pace, allowing the orange color to dispel after each addition, and 
the resulting yellow solution was stirred at 0 ºC.  An LCMS sample taken 1 min after complete 
addition showed full conversion to the dichloride product, so the reaction was quenched by the 
addition of saturated aqueous Na2S2O3.  The resulting mixture was transferred to a separatory 
funnel with and diluted with CH2Cl2 and water, creating a triphasic system with HFIP on bottom, 
CH2Cl2 in the middle, and the aqueous phase on top.  The bottom two phases were collected di-
rectly in a 250 mL roundbottom flask.  The aqueous phase was basified with K2CO3 and extract-
ed with CH2Cl2, draining the organic phase directly into the flask.  The flask was concentrated 
and azeotropically dried twice with toluene.  The product was then purified by column chro-
matography (1% MeOH/CH2Cl2 + 1% NEt3).  White solid, 138.3 mg, 0.251 mmol, 67% yield. 
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1H NMR (500 MHz, CDCl3) δ 5.85 (dd, J = 7.2, 4.1 Hz, 1H), 4.47 (dd, J = 3.7, 1.1 Hz, 1H), 4.04 
(ddd, J = 12.8, 3.7, 2.6 Hz, 1H), 3.90 (s, 3H), 3.82 (dd, J = 15.6, 2.6 Hz, 1H), 3.82 (s, 3H), 3.78 – 
3.76 (m, 1H), 3.77 (s, 3H), 3.72 (s, 3H), 3.42 (dt, J = 10.8, 4.8 Hz, 1H), 3.18 (dd, J = 7.0, 4.8 Hz, 
1H), 3.13 (dd, J = 18.2, 6.7 Hz, 1H), 3.13 – 3.08 (m, 1H), 3.00 (dd, J = 18.1, 1.3 Hz, 1H), 2.45 
(s, 3H), 2.31 (s, 3H), 2.27 (s, 3H), 2.17 (dd, J = 15.6, 12.8 Hz, 1H); 173.3, 156.1, 153.8, 150.4, 
148.3, 130.7, 129.8, 128.0, 127.9, 126.2, 125.6, 124.5, 123.9, 69.1, 60.9, 60.5, 60.4, 60.4, 59.5, 
58.8, 57.6, 52.1, 40.3, 29.5, 24.7, 13.8, 10.1; IR (thin film, NaCl):  3417.7, 2939.6, 1643.6, 
1633.8, 1462.1, 1454.8, 1403.6, 1360.5, 1329.7, 1272.2, 1236.1, 1224.0, 1191.6, 1146.7, 1105.6, 
1081.9, 1004.6, 951.2, 931.7, 833.0, 793.8, 767.9, 736.2, 702.5; HRMS (ESI-TOF) calc’d for 
[M+] C27H32N2O6Cl2 = 550.1637, found 550.1637; [α]D = –119.0º (c = 0.5, CHCl3). 
(6S,9R,14aS,15R)-1,13-dihydroxy-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-
trimethyl-5,6,9,14,14a,15-hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin- 
7-one (29).  Note:  If the reaction vessel is prematurely exposed to air at elevated tempearture, 
aerobic oxidation leads to the formation of quinones, which undergo hydrolysis of the vinylogous 
ester in the presence of CsOH.  The solution must be fully cooled to room temperature prior to 
breaking the seal.  The bisphenol product is otherwise not sensitive to aerobic oxidation, in the 
solid state or in solution.  In a nitrogen-filled glovebox, (2′-Amino-1,1′-biphenyl-2-yl)methane-
sulfonatopalladium(II) dimer (Buchwald’s dimer, 33.5 mg, 0.0453 mmol, 0.500 equiv) and 5-
[di(1-adamantyl)phosphino]-1′,3′,5′-triphenyl-1′H-[1,4′]bipyrazole (AdBippyPhos, 120.2 mg, 
0.181 mmol, 2.00 equiv) were weighed into a scintillation vial and dioxane (8.1 mL) was added. 
The vial was sealed with electrical tape and removed from the glovebox, sonicated briefly, and 
returned to the glovebox.  The resulting tan solution was then transferred to a 20 mL microwave 
vial containing bis-tetrahydroisoquinoline 28 (50.0 mg, 0.0907 mmol, 1.00 equiv) and 
CsOH•H2O (152.3 mg, 0.907 mmol, 10.0 equiv), followed by a 1 mL rinse (9.1 mL total volume, 
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0.01 M in 28).  The vial was sealed, removed from the glovebox, and placed in a preheated 90 ºC 
oil bath.  After 3 h, the vial was removed and allowed to cool fully to room temperature prior to 
removing the seal.  Acetic acid (46.5 µL, 0.813 mmol, 9 equiv) was added to quench remaining 
CsOH and the contents of the vial were transferred to a roundbottom flask, to which silica gel 
and solid KHCO3 (to quench excess acetic acid) were added directly to dry load the crude mix-
ture onto a silica gel column.  The solution was concentrated, and the product was purified by 
column chromatography (2–4–6–8–10% MeOH + CH2Cl2: 200 mL portions, no NEt3 added, 
product elutes in the 6% portion).  Tan solid, 21.4 mg, 0.0416 mmol, 46% yield.  1H NMR (500 
MHz, CDCl3) δ 5.80 (dd, J = 7.2, 4.2 Hz, 1H), 4.34 (d, J = 2.0 Hz, 1H), 3.96 (dt, J = 12.3, 2.5 
Hz, 1H), 3.81 (s, 3H), 3.80 (dd, J = 6.0, 1.0 Hz, 1H), 3.77 (s, 3H), 3.75 (s, 3H), 3.65 (s, 3H), 3.52 
(br s, 1H), 3.47 – 3.40 (m, 2H), 3.23 (dd, J = 10.8, 7.2 Hz, 1H), 3.14 (dd, J = 18.1, 6.7 Hz, 1H), 
3.02 (d, J = 18.0 Hz, 1H), 2.45 (s, 3H), 2.21 (s, 3H), 2.14 (s, 3H), 2.09 (dd, J = 15.2, 12.2 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 173.6, 150.0, 149.7, 146.8, 144.1, 143.5, 143.4, 124.6, 
123.7, 122.6, 118.6, 118.3, 115.9, 69.2, 61.0, 60.9, 60.4, 60.3, 59.6, 59.0, 55.3, 52.5, 40.1, 25.2, 
24.5, 9.7, 9.3; IR (thin film, NaCl):  3332.3, 2937.3, 1613.3, 1462.2, 1453.3, 1413.6, 1353.2, 
1302.2, 1191.4, 1108.8, 1068.0, 1005.9, 910.3, 836.1, 806.3, 730.6; HRMS (ESI-TOF) calc’d for 
[M+] C27H34N2O8 = 514.2315, found 514.2311; [α]D = –91.6º (c = 0.5, CHCl3). 
(6S,7R,9R,14aS,15R)-1,13-dihydroxy-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-
trimethyl-6,7,9,14,14a,15-hexahydro-5H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinoline-
7-carbonitrile (34).  In an oven-dried vial, LiAlH4 solution (1.0 M in THF, 2 mL, 2.0 mmol) was 
cooled to 0 ºC.  A solution of ethyl acetate (230 µL, 2.35 mmol) in 2 mL THF was added slowly, 
and the resulting solution was stirred 30 min at 0 ºC, providing a 0.47 M solution of 
Li(EtO)2AlH2 in THF.  bis-Tetrahydroisoquinoline 29 (49.0 mg, 0.095 mmol, 1.0 equiv) was dis-
solved in THF (4.8 mL, 0.02 M) and the resulting solution was cooled to 0 ºC.  A solution of 
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Li(EtO)2AlH2 (0.47 M in THF, 3.0 mL, 1.43 mmol, 15.0 equiv) was added slowly, resulting in 
extensive evolution of H2.  After stirring 50 min, the reaction was quenched with acetic acid (115 
µL, 2.00 mmol, 21 equiv) and aqueous potassium cyanide (4.8 M, 120 µL, 0.571 mmol, 6.0 
equiv) was added, followed by celite and anhydrous Na2SO4 (roughly 1 g each).  The solution 
was diluted with 8 mL THF and stirred 10 h, warming to room temperature.  More celite was 
added, and the suspension was filtered through celite, rinsing with EtOAc.  The filtrate was 
transferred to a roundbottom flask and was concentrated.  At this stage, LCMS revealed a ~4:1 
mixture of product 34 and starting material 29, so the crude mixture was resubjected to the re-
duction conditions, using 3 mL THF as the reaction solvent and 1 mL of freshly prepared 
Li(EtO)2AlH2 solution.  After 10 min, LCMS showed minimal conversion of the remaining start-
ing material, with some over-reduced product (m/z = 501).  The reaction mixture was quenched 
and worked up as described above.  The product was purified by column chromatography (50–
75–100% EtOAc/hex, 200 mL each; product elutes in the 75% portion).  Colorless solid, 25.2 
mg, 47.9 µmol, 50% yield.  1H NMR (400 MHz, CDCl3) δ 4.19 (dD, J = 2.7, 1.1 Hz, 1H), 4.00 – 
4.05 (m, 2H), 3.81 (s, 3H), 3.751 (s, 3H), 3.749 (s, 3H), 3.70 (s, 3H), 3.56 (dd, J = 10.9, 4.4 Hz, 
1H), 3.40 (ddd, J = 7.5, 2.5, 1.2 Hz, 1H), 3.31 (dt, J = 12.1, 2.7 Hz, 1H), 3.18 (d, J = 9.4 Hz, 
1H), 3.13 (dd, J = 15.6, 2.7 Hz, 1H), 3.10 (dd, J = 18.6, 7.8 Hz, 1H), 2.51 (d, J = 18.6 Hz, 1H), 
2.34 (s, 3H), 2.22 (s, 3H), 2.09 (s, 3H), 1.85 (dd, J = 15.6, 12.0 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 149.6, 148.7, 146.6, 143.7, 143.4, 143.1, 125.4, 123.5, 122.7, 118.1, 118.0, 117.1, 
116.7, 66.2, 61.2, 61.0, 60.8, 60.4, 60.2, 58.5, 57.1, 56.7, 55.2, 41.9, 25.4, 21.7, 9.8, 9.0; IR (thin 
film, NaCl): 3427.6, 2936.1, 2832.7, 2228.1, 1606.8, 1463.2, 1412.1, 1384.5, 1349.9, 1319.9, 
1300.9, 1251.3, 1218.1, 1191.3, 1150.7, 1107.7, 1070.1, 1001.7, 981.7, 907.7, 875.4, 829.8, 
754.4; HRMS (ESI-TOF) calc’d for [M+] C28H35N3O7 = 525.2475, found 525.2471; [α]D = 
+22.9º (c = 0.5, CHCl3). 
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(–)-Jorunnamycin A (3).  bis-Tetrahydroisoquinoline 34 (22.0 mg, 41.9 µmol, 1.0 equiv) and 
4,5-dichloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile (DDQ, 38.0 mg, 167 µmol, 4.0 
equiv) were weighed into a roundbottom flask and 8.4 mL of a 9:1 mixture of acetone and water 
was added (0.005 M).  The purple solution gradually turned blood red.  After 1 h, the reaction 
was quenched with saturated aqueous NaHCO3.  The phases were separated and the aqueous 
phase was extracted with ethyl acetate.  The combined organic phases were washed with brine, 
dried over Na2SO4 and concentrated.  The product was purified using reverse-phase (C18) prepar-
ative HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 254 nm, 20–
70% MeCN over 5 min, hold at 70% for 3 min, hold at 95% for 3 min.  Product 3 has tR = 7.2 
min).  Yellow film, 6.6 mg, 13.4 µmol, 32% yield.  1H NMR (500 MHz, CDCl3) δ 4.11 (d, J = 
2.6 Hz, 1H), 4.08 (dd, J = 3.0, 1.0 Hz, 1H), 4.03 (s, 3H), 3.99 (s, 3H), 3.90 (app q, J = 3.1 Hz, 
1H), 3.71 (dd, J = 11.3, 3.4 Hz, 1H), 3.50 (br s, 1H), 3.42 (ddd, J = 7.4, 2.6, 1.5 Hz, 1H), 3.18 
(dt, J = 11.4, 2.9 Hz, 1H), 2.93 (ddd, J = 17.4, 2.8, 0.9 Hz, 1H), 2.83 (dd, J = 21.0, 7.5 Hz, 1H), 
2.31 (s, 3H), 2.26 (d, J = 21.0 Hz, 1H), 1.95 (s, 3H), 1.94 (s, 3H), 1.41 (ddd, J = 17.5, 11.5, 2.7 
Hz, 1H); IR (thin film, NaCl): 3508.5, 2943.0, 2226.8, 1651.8, 1620.8, 1447.2, 1373.6, 1310.6, 
1277.4, 1236.0, 1190.6, 1151.1, 1098.1, 1077.8, 963.7, 886.8, 775.3; HRMS (ESI-TOF) calc’d 
for [M+] C26H27N3O7 = 493.1849, found 493.1848; [α]D = –94.3º (c = 0.35, CHCl3). 
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(33% yield)
(6S,7R,9R,10R,14aS,15R)-10-hydroxy-9-(hydroxymethyl)-2,10,11-trimethoxy-3,12,16-
trimethyl-1,4,13-trioxo-1,5,6,7,9,10,13,14,14a,15-decahydro-4H-6,15-epiminobenzo[4,5]azo-
cino[1,2-b]isoquinoline-7-carbonitrile (30).  Product 30 was also isolated from the preparative 
HPLC method described above, with tR = 9.3 min.  Yellow film, 7.3 mg, 13.9 µmol, 33% yield. 
The structure was assigned using diagnostic nOe correlations (highlighted methoxy groups) and 
HMBC correlations (C13 to C14 but not C9, C1 to C15 and C5, C4 to C15 and C5).  1H NMR 
(400 MHz, CDCl3) δ 4.54 (t, J = 7.7 Hz, 1H), 4.16 (dd, J = 3.8, 1.5 Hz, 1H), 4.08 (s, 3H), 4.00 
(s, 3H), 3.74 (dd, J = 7.8, 5.8 Hz, 1H), 3.66 (d, J = 2.6 Hz, 1H), 3.43 (ddd, J = 7.8, 2.8, 1.7 Hz, 
1H), 3.29 (dt, J = 10.8, 4.2 Hz, 1H), 3.13 (s, 3H), 2.82 (dd, J = 20.9, 7.8 Hz, 1H), 2.62 (ddd, J = 
18.6, 4.6, 3.0 Hz, 1H), 2.28 (s, 3H), 2.13 (d, J = 20.9 Hz, 1H), 1.93 (s, 3H), 1.75 (s, 3H), 1.68 (br 
s, 1H, OH), 1.52 (ddd, J = 18.5, 10.7, 3.1 Hz, 1H); 13C NMR (400 MHz, CDCl3) δ 186.6, 185.2, 
182.7, 160.4, 155.9, 143.2, 141.2, 136.2, 128.5, 127.7, 117.9, 116.0, 99.0, 74.2, 61.2, 60.5, 59.1, 
56.0, 55.6, 54.6, 53.9, 51.8, 41.9, 26.0, 21.5, 8.8, 7.9; IR (thin film, NaCl):  3445.7, 3013.6, 
2952.6, 2853.8, 2226.1, 1643.9, 1615.0, 1455.3, 1412.8, 1373.4, 1318.1, 1272.0, 1247.5, 1189.2, 
1153.9, 1091.9, 1060.9, 1025.7, 990.6, 973.3, 950.1, 895.6, 878.0, 759.4, 720.6, 666.1; HRMS 
(ESI-TOF) calc’d for [M–OH]+ C27H29N3O7 = 493.1849, found 493.1848; [α]D = –94.3º (c = 
0.35, CHCl3). 
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(–)-Jorumycin (1).  In a 1-dram vial, Jorunnamycin A (3, 6.6 mg, 13.4 µmol, 1.0 equiv) and 4-
dimethylaminopyridine (DMAP, 4.9 mg, 40.1 µmol, 3.0 equiv) were dissolved in acetonitrile 
(400 µL, 0.03 M) and acetic anhydride (3.8 µL, 40.1 µmol, 3.0 equiv) was added neat.  The 
brown solution immediately turned yellow.  After 30 minutes, LCMS showed complete conver-
sion to the acetylated intermediate.  At this stage, silver nitrate (57.0 mg, 334 µmol, 25.0 equiv) 
and water (260 µL) were added in rapid succession.  The vial was resealed and placed in a pre-
heated 45 ºC heating block, then protected from light with aluminum foil.  After 30 minutes, 
LCMS showed complete conversion to (–)-jorumycin (1), so the solution was filtered to remove 
AgCN and silver black, and the crude reaction mixture was purified directly using preparative 
HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 265 nm, 10–55% 
MeCN over 7 min, ramp to 95% MeCN over 0.2 min, hold at 95% for 1.8 min for a total run 
time of 9 min.  Product has tR = 6.6 min).  Yellow film, 4.8 mg, 9.12 µmol, 68% yield.  1H NMR 
(500 MHz, CDCl3) δ 4.44 (dd, J = 11.2, 3.5 Hz, 1H), 4.44 (br s, 1H), 4.37 (d, J = 3.1 Hz, 1H), 
4.01 (s, 3H), 3.99 (s, 3H), 3.92 (br s, 1H), 3.82 (dd, J = 11.3, 3.4 Hz, 1H), 3.21 – 3.16 (m, 1H), 
3.14 (dd, J = 7.3, 4.7 Hz, 1H), 2.84 (dd, J = 16.6, 2.4 Hz, 1H), 2.66 (dd, J = 21.1, 7.6 Hz, 1H), 
2.27 (s, 3H), 2.23 (d, J = 21.0 Hz, 1H), 1.96 (s, 3H), 1.94 (s, 3H), 1.76 (s, 3H), 1.24 (ddd, J = 
16.6, 11.3, 2.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 186.0, 181.4, 170.2, 155.8, 155.4, 142.1, 
142.0, 137.4, 128.9, 128.5, 83.1, 64.4, 61.19, 61.17, 57.6, 54.4, 52.9, 51.1, 41.6, 25.7, 20.74, 
20.69, 8.9, 8.8; IR (thin film, NaCl): 3478.3, 2923.5, 2850.7, 1738.4, 1651.6, 1620.8, 1449.0, 
1373.6, 1309.4, 1260.4, 1233.9, 1188.7, 1149.6, 1096.2, 1083.0, 1013.2, 901.9, 871.7, 839.6, 
801.2, 730.2; HRMS (ESI-TOF) calc’d for [M+] C27H30N2O9 = 526.1951, found 526.1956; [α]D 
= –86.8º (c = 0.1, CHCl3).   
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Note: After purification via the method as described above (preparative HPLC using MeCN and 
0.4% AcOH in H2O with lyophilization of the product-containing fractions), we obtained jo-
rumycin as a yellow solid in high purity as determined from the following LCMS trace (TIC): 
Following this method of purification, a sample was prepared for NMR spectroscopy using 
CDCl3 that had been freshly distilled from flame-dried K2CO3, and a 1H spectrum was recorded 
within minutes of preparing the sample.  Despite all of our precautions, significant impurities 
were present in the spectrum at 1.25 ppm, 2–2.25 ppm, and 5–6 ppm.  The sample was immedi-
ately tested for purity using the same LCMS method as above and provided the following chro-
matogram (TIC): 
Many attempts to repurify our samples were made, including repurification via the method de-
scribed above, preparative HPLC with MeCN and H2O in the absence of AcOH, column chro-
matography with 1% MeOH in CH2Cl2 in the presence or absence of NEt3, and column chro-
matography on SiO2 or basic alumina with EtOAc in the absence of NEt3.  In all cases, spectra 
containing the impurities described above were obtained, independent of the method of purifica-
tion.  This leads us to conclude that jorumycin is not stable in chloroform; this is also consistent 
to observations made in the isolation report (21).  The optical rotation listed above was mea-
sured by repurifying the product as originally described and dissolving the sample in CHCl3 that 
had been freshly distilled from flame-dried K2CO3 immediately prior to recording its optical ro-
tation to minimize decomposition, and this method provided a value in good agreement with pre-
vious literature (15–20); however, a 1H NMR spectrum of this sample showed the same impuri-
ties described above.  We therefore conclude that future synthetic endeavors should avoid the use 
of chloroform as a solvent for analytical characterization (51, 52).  We are currently working to 
obtain the requisite data in a solvent such as benzene or acetonitrile. 
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Tabulated NMR Data for Hemiacetal 30, Jorunnamycin A (3), and Jorumycin (1). 
Table S1.  Tabulated NMR data and assignments for hemiacetal 30. 
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1H NMR 13C NMR
Hydroxymethyl 4.54 (t, J = 7.7 Hz, 1H) 186.6
C15 4.16 (dd, J = 3.8, 1.5 Hz, 1H) 185.2
OMe 4.08 (s, 3H) 182.7
OMe 4.00 (s, 3H) 160.4
Hydroxymethyl 3.74 (dd, J = 7.8, 5.8 Hz, 1H) 155.9
C7 3.66 (d, J = 2.6 Hz, 1H) 143.2
C6 3.43 (ddd, J = 7.8, 2.8, 1.7 Hz, 1H) 141.2
α-amino (between C14 and C15) 3.29 (dt, J = 10.8, 4.2 Hz, 1H) 136.2
Hemiacetal OMe 3.13 (s, 3H) 128.5
C5 2.82 (dd, J = 20.9, 7.8 Hz, 1H) 127.7
C1 2.62 (ddd, J = 18.6, 4.6, 3.0 Hz, 1H) 117.9
NMe 2.28 (s, 3H) 116.0
C4 2.13 (d, J = 20.9 Hz, 1H) 99.0
Me 1.93 (s, 3H) 74.2
Me 1.75 (s, 3H) 61.2
OH 1.63 (br s, 1H, OH), 60.5
C1 1.52 (ddd, J = 18.5, 10.7, 3.1 Hz, 1H) 59.1
56.0
55.6
54.6
53.9
51.8
41.9
26.0
21.5
8.8
7.9
MeO
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(33% yield)
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Table S2.  Tabulated NMR data for (–)-Jorunnamycin A (3). 
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Jorunnamycin A (3)
Synthetic Jorunnamycin A,                      
1H NMR
Authentic Jorunnamycin A (Ref. 15),               
1H NMR
Synthetic 
Jorunnamycin A,        
13C NMR
Authentic 
Jorunnamycin A 
(Ref. 15), 13C NMR
4.11 (d, J = 2.6 Hz, 1H) 4.08 (d, J = 2.3 Hz, 1H) 186.4 186.5
4.08 (dd, J = 3.0, 1.0 Hz, 1H) 4.06 (app d, J = 2.1 Hz, 1H) 185.6 185.7
4.03 (s, 3H) 4.01 (s, 3H) 182.4 182.5
3.99 (s, 3H) 3.97 (s, 3H) 181.5 181.6
3.90 (app q, J = 3.1 Hz, 1H) 3.87 (ddd, J = 5.8, 3.0, 3.0 Hz, 1H) 155.6 155.7
3.71 (dd, J = 11.3, 3.4 Hz, 1H) 3.69 (dt, J = 11.5, 2.8 Hz, 1H) 155.5 155.6
3.50 (br s, 1H) 3.48 (m, 1H) 141.8 141.8
3.42 (ddd, J = 7.4, 2.6, 1.5 Hz, 1H) 3.39 (app d, J = 7.5 Hz, 1H) 141.5 141.6
3.18 (dt, J = 11.4, 2.9 Hz, 1H) 3.15 (dt, J = 11.5, 2.8 Hz, 1H) 136.2 136.3
2.93 (ddd, J = 17.4, 2.8, 0.9 Hz, 1H) 2.91 (dd, J = 17.5, 2.6 Hz, 1H) 135.8 135.8
2.83 (dd, J = 21.0, 7.5 Hz, 1H) 2.81 (dd, J = 20.9, 7.5 Hz, 1H) 129.1 129.1
2.31 (s, 3H) 2.28 (s, 3H) 128.8 128.8
2.26 (d, J = 21.0 Hz, 1H) 2.23 (d, J = 21.1 Hz, 1H) 117.0 117.0
1.95 (s, 3H) 1.93 (s, 3H) 64.1 64.2
1.94 (s, 3H) 1.92 (s, 3H) 61.3 61.3
1.41 (ddd, J = 17.5, 11.5, 2.7 Hz, 1H) 1.38 (ddd, J = 17.3, 11.5, 2.6 Hz, 1H) 61.3 61.3
59.1 59.2
58.1 58.2
54.6 54.7
54.4 54.5
54.4 54.4
41.8 41.8
25.5 25.6
21.6 21.7
9.0 9.0
8.9 8.9
MeO
O
Me
N
N
OH
CN
H
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Me
O
Me
O
O
3
(32% yield)
Table S3.  Tabulated data for (–)-Jorumycin (1).  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Jorumycin (1)
Synthetic Jorumycin,                               
1H NMR
Authentic Jorumycin (Ref. 15),               
1H NMR
Synthetic 
Jorumycin,           
13C NMR
Authentic 
Jorumycin (Ref. 
15), 13C NMR
4.47 – 4.41 (m, 1H) 4.41 (dd, J = 11.1, 3.4 Hz, 1H), 186.7 186.8
4.44 (dd, J = 11.2, 3.5 Hz, 1H) 4.41 (d, J = 11.1 Hz, 1H), 186.0 186.1
4.36 (q, J = 3.6, 3.2 Hz, 1H) 4.35 (ddd, J = 5.5, 2.8, 2.8 Hz, 1H), 186.7 182.8
4.00 (s, 3H) 3.98 (s, 3H), 181.5 181.6
3.98 (s, 3H) 3.96 (s, 3H), 170.2 170.3
3.90 (app d, J = 2.5 Hz, 1H) 3.88 (app d, J = 2.7 Hz, 1H), 155.8 155.9
3.88 (br s, 1H, C21-OH) 3.86 (d, J = 10.9 Hz, 1H, C21-OH), 155.4 155.5
3.81 (dd, J = 11.2, 3.3 Hz, 1H) 3.80 (dd, J = 11.1, 3.2 Hz, 1H), 142.1 142.2
3.20 – 3.12 (m, 2H) 3.16 (m, 1H), 142.0 142.1
3.14 (m, 1H), 137.4 137.5
2.84 (dd, J = 16.7, 2.2 Hz, 1H) 2.82 (dd, J = 16.8, 2.3 Hz, 1H), 134.6 134.7
2.65 (dd, J = 21.0, 7.5 Hz, 1H) 2.63 (dd, J = 21.1, 7.5 Hz, 1H), 128.9 129.0
2.26 (s, 3H) 2.24 (s, 3H), 128.5 128.6
2.23 (d, J = 18.8 Hz, 1H) 2.22 (d, J = 20.0 Hz, 1H), 83.2 83.2
1.96 (s, 3H) 1.94 (s, 3H), 64.3 64.4
1.93 (s, 3H) 1.91 (s, 3H), 61.2 61.2
1.76 (s, 3H) 1.74 (s, 3H), 61.2 61.2
1.28 (dd, J = 11.5, 2.6 Hz, 1H) 1.24 (ddd, J = 16.6, 11.3, 2.6 Hz, 1H) 57.6 57.7
54.3 54.4
52.9 52.9
51.2 51.3
41.6 41.7
25.8 25.8
20.7 20.8
20.6 20.7
9.0 9.0
8.8 8.9
MeO
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Me
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Optimization of the Enantioselective Hydrogenation. 
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TBAI, L*
H2 (60 bar)
60 ºC, 18 h
(R = CO2Me)
Entry Ligand Yield 22 ee 22 Yield 6
L1 SL-J001-1 — — —
L2 SL-J002-1 — — —
25 Xyliphos 26% 80% —
L3 SL-J216-1 — — —
L4 SL-J404-1 68% –15% —
L5 SL-J006-1 — — —
26 BTFM-Xyliphos 83% 94% 10%
L6 SL-J007-1 — — —
L7 SL-J013-1 — — —
L8 SL-J418-1 30% –77% —
L9 SL-J212-1 — — —
L10 SL-J015-1 22% –16% —
L11 SL-J003-2 — — —
L12 SL-J009-1 — — —
L13 SL-J004-1 — — —
L14 SL-J502-1 — — —
L15 SL-J505-1 — — —
L16 SL-W002-1 — — —
L17 SL-W006-1 — — —
L18 SL-W001-1 2% ND —
L19 SL-W005-1 6% ND —
L20 SL-W003-1 4% ND —
S !40
Entry Ligand Yield 22 ee 22 Yield 6
L21 SL-W008-1 2% ND —
L22 SL-W009-1 — — —
L23 SL-W022-1 — — —
L24 BINAP — — —
L25 BINAPINE 6% ND —
L26 MeO-BIBOP <1% ND —
L27 DTB-MeOBIPHEP — — —
L28 DTBM-MeOBIPHEP — — —
L29 SEGPHOS <1% ND —
L30 DM-SEGPHOS — — —
L31 C3-TunePhos — — —
L32 DIFLUORPHOS 14% 62% —
L33 SYNPHOS — — —
L34 SL-M001-2 23% 32% —
L35 SL-M012-2 6% ND —
L36 SL-M003-2 55% –27% —
L37 SL-T001-1 88% –17% —
L38 SL-T002-1 — — —
L39 SL-N004-1 — — —
L40 t-Bu-PHOX 1% ND —
23 (CF3)-t-BuPHOX 22% –82% —
L41 QUINAP 6% ND —
L42 Me-BPE 30% 26% —
L43 Et-BPE 31% 16% —
L44 i-Pr-BPE 2% ND —
L45 Me-DUPHOS 11% ND —
L46 Et-DUPHOS 12% ND —
L47 DuanPhos 3% ND —
L48 catASium MNXyl(S) 36% 0% —
L49 catasium MNXylF(S) 12% ND —
24 Et-FerroTANE 26% 87% —
Table S4.  Results of 66 ligands tested in the asymmetric hydrogenation of 8. 
S !41
Entry Ligand Yield 22 ee 22 Yield 6
L50 Me-Ferrocelane <1% ND —
L51 i-Pr-Ferrocelane — — —
L52 DIOP 16% 6% —
L53 SolPhos — — —
L54 P-Phos 7% 46% —
L55 PhanePhos 31% 10% —
L56 Xyl-PhanePhos 15% 58% —
L57 SDP 4% ND —
L58 SKP — — —
L59 Chiraphos 48% 13% —
L60 BDPP 8% ND —
L61 catASium D 20% 47% —
L62 BPPM 8% ND —
L63 NorPhos 65% 38% —
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<1 %, ee ND -- -- <1 %, ee ND
L30:  DM-SEGPHOS L31:  C3-TunePhos L32:  Difluorphos L34:  SL-M001-2 L35:  SL-M012-2
-- -- 14%, 62% ee -- 23%, 32% ee 6%
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(R = CO2Me)
yield and ee of 22Josiphos lig. R1 R2
--L1:  SL-J001-1 Ph Cy
L2:  SL-J002-1 Ph t-Bu
26%, 80% ee25:  SL-J005-2 Ph Xyl
--L3:  SL-J216-1 1-Nap t-Bu
68%, –15% eeL4:  SL-J404-1 1-Nap Xyl
--L5:  SL-J006-1 BTFM Cy
83%, 94% ee26:  SL-J008-1 BTFM Xyl
--L6:  SL-J007-1 DMM-Ph Cy
--L7:  SL-J013-1 DMM-Ph t-Bu
30%, –77% eeL8:  SL-J418-1 DMM-Ph Xyl
--L9:  SL-J212-1 2-fur t-Bu
22%, –16% eeL10:  SL-J015-1 2-fur Xyl
L11:  SL-J003-2 Cy Cy
--L12:  SL-J009-1 Cy t-Bu
--L13:  SL-J004-1 Cy Ph
--L14:  SL-J502-1 t-Bu Ph
--L15:  SL-J505-1 t-Bu o-Tol
-- Fe
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L17:  SL-W006-1 Ph Xyl
2%, ee NDL18:  SL-W001-1 Ph BTFM
6%, ee NDL19:  SL-W005-1 DMM-Ph BTFM
4%, ee NDL20:  SL-W003-1 Ph Cy
2%, ee NDL21:  SL-2008-1 Cy BTFM
--L22:  SL-W009-1 Xyl Xyl
--L23:  SL-W022-1 Ph norbornyl
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Figure S1.  Results of 66 ligands tested in the asymmetric hydrogenation of 8, including the    
ligands’ structures. 
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L41:  QUINAP L42:  Me-BPE L43:  Et-BPE L44:  i-Pr-BPE L45:  Me-DUPHOS L46:  Et-DUPHOS
6%, ee ND 30%, 26% ee 31%, 16% ee 2%, ee ND
L36:  SL-M003-2 L37:  SL-T001-1 L38:  SL-T002-1 L39:  SL-N004-1 L40:  t-Bu-PHOX 23:  (CF3)-t-Bu-PHOX
55%, –27% ee 88%, –17% ee <1%, ee ND -- 1%, ee ND 22%, –82% ee
L47:  DuanPhos L48:  catASium MNXyl(S) L49:  catASium MNXylF(S) 24:  Et-FerroTANE L50:  Me-Ferrocelane L51:  i-Pr-Ferrocelane
3%, ee ND 36%, 0% ee 12%, ee ND 26%, –87% ee < 1%, ee ND --
L53:  SolPhos
L54:  P-Phos
L55:  PhanePhos L56:  Xyl-PhanePhos
16%, 6% ee --
7%, 46% ee
31%, 10% ee 15%, 58% ee 4%, ee ND
L59:  Chiraphos L61:  catASium D L62:  BPPM L63:  NorPhos
-- 48%, 13% ee 8%, ee ND 20%, 47% ee 8% yield, ee ND 65%, 38% ee
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Explanation of Selectivity Differences Between Products 22 and 6. 
Figure S2.  While the D-ring is electronically activated to receive nucleophilic hydritic M–H 
bonds, the directing affect of the hydroxymethyl group appended to the B-ring appears to be a 
more strongly activating group. 
Figure S3.  Of all the ligands tested, only BTFM-Xyliphos enables the further reduction of 22 to 
6 following lactamization.  Intriguingly, the product 22 shows a 94% ee, while product 6 only 
shows 87% ee.  We propose that the discrepancy in enantioenrichment of the products is due to 
competitive D-ring reduction with lower enantioselectivity than that observed when the B-ring is 
reduced first.  Because no other diastereomers are observed, global reduction via this route also 
appears to be fully diastereoselective.   
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D-ring:  Electronically activated by ester for hydritic reduction
B-ring reduction:  fast with all successful ligands
D-ring reduction:  only observed with BTFM-Xyliphos (26) ligation8
Conclusion:  Hydroxyl direction lowers activation energy more than electronic activation
N
N
Me
MeO
OMe
MeO
Me
OMe
R
OH 8
[Ir(cod)Cl]2, TBAI
N
NH
H
Me
MeO
OMe
OH
O
OMe
Me
OMe
6
NH
N
Me
MeO
OMe
MeO
Me
OMe
R
OH 22
BTFM-Xyliphos
H2 (60 bar)
60 ºC, 18 h
(R = CO2Me)
excess Ac2O added
to crude rxn mixture
NAc
N
Me
MeO
OMe
MeO
Me
OMe
CO2Me
OH
S12
22 was found to be unstable
to isolation, presumably due to
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>20:1
>20:1
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 Figure S4.  Path A is faster than Path B for all ligands to such an extent that Path B is only ob-
served when the most activating ligand, BTFM-Xyliphos, is used.  Both partially reduced inter-
mediates are expected to form tridentate chelates to the metal to form 22•M and S13•M (with M 
not necessarily being the catalytically active metal), with the three dimensional structures of each 
leading to the all-syn product as the major diastereomer.  Furthermore, because B-ring reduction 
appears to be faster than D-ring reduction in all cases, intermediate 22 can be isolated (after N-
protection) while intermediate S12 has never been directly observed.  The discrepancy in enan-
tiomeric excess between intermediate 22 and fully hydrogenated intermediate 7 (as manifested 
by the enantiomeric excess of S12 and bis-THIQ 6, respectively) can be explained if the enan-
tioselectivity of Path B is significantly lower than that of Path A.  As the two paths converge onto 
the same product, in this scenario the enantiopurity of 6 would be expected to be less than that of 
22. 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Synthesis of Derivatives 31–34.
(6S,7R,9R,14aS,15R)-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-trimethyl- 
6,7,9,14,14a,15-hexahydro-5H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinoline-7-carboni-
trile (31). In an oven-dried vial, LiAlH4 solution (1.0 M in THF, 2 mL, 2.0 mmol) was cooled to 
0 ºC.  A solution of ethyl acetate (230 µL, 2.35 mmol) in 2 mL THF was added slowly, and the 
resulting solution was stirred 30 min at 0 ºC, providing a 0.47 M solution of Li(EtO)2AlH2 in 
THF.  bis-Tetrahydroisoquinoline 6 (8.0 mg, 16.6 µmol, 1.0 equiv) was dissolved in THF (0.75 
mL, 0.02 M) and the resulting solution was cooled to 0 ºC.  A solution of Li(EtO)2AlH2 (0.47 M 
in THF, 0.47 mL, 0.21 mmol, 15.0 equiv) was added slowly, resulting in extensive evolution of 
H2.  After stirring 45 min, the reaction was quenched with acetic acid (17.7 µL, 0.31 mmol, 21 
equiv) and aqueous potassium cyanide (4.8 M, 18.4 µL, 88.4 µmol, 6.0 equiv) was added, fol-
lowed by celite and anhydrous Na2SO4 (roughly 300 mg each).  The solution was diluted with 1 
mL THF and stirred 10 h, warming to room temperature.  More celite was added, and the suspen-
sion was filtered through celite, rinsed with EtOAc, and concentrated. The product was purified 
by preparative HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 230 
nm, 35–95% MeCN over 8 min, hold at 95% for 1 min for a total run time of 9 min.  Product 31 
has tR = 6.5 min).  Colorless solid, 3.9 mg, 7.9 µmol, 48% yield.  1H NMR (400 MHz, CDCl3) δ 
6.57 (s, 1H), 6.23 (s, 1H), 4.02 (d, J = 2.4 Hz, 1H), 3.99 (t, J = 4.4 Hz, 1H), 3.80 (s, 3H), 3.75 (s, 
3H), 3.69 (s, 3H), 3.66 (s, 3H), 3.55 – 3.51 (m, 1H), 3.48 (d, J = 10.4 Hz, 1H), 3.36 (d, J = 7.7 
Hz, 1H), 3.25 (dt, J = 12.1, 2.6 Hz, 1H), 3.13 – 3.07 (m, 1H), 3.05 (dd, J = 18.4, 7.8 Hz, 1H), 
2.49 – 2.39 (m, 2H), 2.31 (s, 3H), 2.25 – 2.16 (m, 1H), 2.13 (s, 3H), 2.06 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 155.4, 148.5, 148.1, 130.0, 129.2, 124.9, 124.2, 123.5, 118.1, 117.7, 116.9, 
107.3, 106.2, 64.9, 62.4, 61.3, 60.1, 59.3, 58.9, 57.5, 55.5, 54.8, 54.6, 40.7, 31.8, 20.6, 14.7, 8.0; 
S !46
then, AcOH, aq. KCN MeO
OMe
Me
N
(48% yield)
N
OH
CN
H
OMe
Me
OMe
MeO
OMe
Me
N
N
OH
O
H
OMe
Me
OMe
Me
H
H
Me Li(EtO)2AlH2, THF, 0 ºC
H
H
316
IR (thin film, NaCl): 3440.8, 2961.2, 2928.4, 2855.0, 1607.1, 1455.7, 1410.2, 1325.6, 1260.8, 
1190.0, 1122.9, 1082.1, 1029.4, 912.2, 864.5, 801.0, 733.7; HRMS (ESI-TOF) calc’d for [M+] 
C28H35N3O5 = 493.2577, found 493.2579; [α]D = –43.3º (c = 0.05, CHCl3). 
(6S,9R,14aS,15R)-13-chloro-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-trimethyl- 
5,6,9,14,14a,15-hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-7-one (S13) 
and (6S,9R,14aS,15R)-1-chloro-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-tri-
methyl-5,6,9,14,14a,15-hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-7-
one (S14). bis-Tetrahydroisoquinoline S11 (112.0 mg, 0.232 mmol, 1.0 equiv) was dissolved in 
HFIP (11.6 mL, 0.02 M after complete addition) and the solution was cooled to 0 ºC.  N-
Chlorosaccharine (55.6 mg, 0.255 mmol, 1.1 equiv) was dissolved in 1.6 mL HFIP and this solu-
tion was added at a slow dropwise pace, allowing the orange color to dispel after each addition, 
and the resulting yellow solution was stirred at 0 ºC.  An LCMS sample taken 1 min after com-
plete addition showed a 2.5:1.7:1.0:1.5 mixture of starting material S11:S13:S14: dichlorinated 
product 28. The reaction was quenched by the addition of saturated aqueous Na2S2O3 and trans-
ferred to a separatory funnel with CH2Cl2 and water, creating a triphasic system with HFIP on 
bottom, CH2Cl2 in the middle, and the aqueous phase on top.  The bottom two phases were col-
lected.  The aqueous phase was basified with K2CO3 and extracted with CH2Cl2.  The combined 
organic phases were concentrated and azeotropically dried twice with benzene.  Products S13 
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and S14 were isolated using preparative HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/min, 
monitor wavelength = 235 nm, 50–80% MeCN over 10 min, ramp to 95% MeCN over 0.5 min, 
hold at 95% for 2.5 min for a total run time of 13 min.  Starting material S11, product S13, and 
S14 has tR = 3.1, 5.1, and 6.7 min, respectively). Starting material S11 was recovered as a color-
less solid, 24.3 mg, 0.050 mmol, 22% yield. S13 was isolated as a white solid, 25.2 mg, 0.049 
mmol, 21% yield, and 27% yield based on recovered starting material. S14 is a white solid, 13.7 
mg, 0.026 mmol, 11% yield, 15% yield based on recovered starting material. The structures of 
S13 and S14 were assigned using diagnostic nOe correlations (highlighted methoxy or methyl 
groups).
Product S13: 1H NMR (400 MHz, CDCl3) δ 6.42 (s, 1H), 5.75 (dd, J = 6.4, 4.0 Hz, 1H), 3.95 
(ddd, J = 12.6, 3.6, 2.5 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.84 – 3.78 (m, 2H), 3.77 (s, 3H), 
3.69 (s, 3H), 3.40 (dd, J = 11.0, 4.0 Hz, 1H), 3.26 (dd, J = 15.2, 2.5 Hz, 1H), 3.18 (dd, J = 10.9, 
6.4 Hz, 2H), 3.12 (d, J = 6.6 Hz, 1H), 2.94 (dd, J = 17.7, 1.3 Hz, 1H), 2.47 (s, 3H), 2.41 (dd, J = 
15.2, 12.6 Hz, 1H), 2.31 (s, 3H), 2.14 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 173.1, 157.4, 
156.8, 150.4, 148.5, 130.6, 129.7, 128.5, 127.5, 126.2, 119.8, 118.7, 107.0, 68.8, 61.1, 60.9, 60.4, 
60.4, 60.1, 57.6, 55.9, 52.7, 40.0, 30.6, 24.0, 13.8, 9.1; IR (thin film, NaCl): 3387.5, 2938.1, 
1634.1, 1455.8, 1407.0, 1330.2, 1123.8, 1081.0, 1013.2, 754.4; HRMS (ESI-TOF) calc’d for 
[M+H]+ C27H34ClN2O6 = 517.2100, found 517.2082; [α]D = –73.6º (c = 0.89, CHCl3).  
Product S14: 1H NMR (400 MHz, CDCl3) δ 6.73 (s, 1H), 5.85 (dd, J = 7.5, 4.2 Hz, 1H), 4.46 – 
4.39 (m, 1H), 4.08 (dt, J = 12.9, 2.9 Hz, 1H), 3.90 (s, 3H), 3.80 (s, 3H), 3.77 (s, 4H), 3.71 (s, 
4H), 3.44 (dd, J = 10.8, 4.2 Hz, 1H), 3.22 – 3.06 (m, 3H), 3.00 (dd, J = 18.1, 1.3 Hz, 1H), 2.43 
(s, 3H), 2.39 – 2.29 (m, 1H), 2.26 (s, 3H), 2.23 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 173.3, 
156.0, 153.6, 149.8, 149.4, 131.7, 131.3, 127.8, 126.1, 124.8, 124.4, 124.2, 123.5, 69.0, 60.6, 
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60.4, 60.3, 59.9, 59.3, 59.2, 57.6, 52.0, 40.1, 31.7, 24.8, 15.7, 10.0; IR (thin film, NaCl): 3418.3, 
2939.3, 2870.0, 1643.7, 1633.8, 1454.9, 1446.2, 1325.6, 1224.2, 1105.8, 1080.7, 1004.5, 931.9, 
755.2; HRMS (ESI-TOF) calc’d for [M+H]+ C27H34ClN2O6 = 517.2100, found 517.2101; [α]D = 
–114.0º (c = 0.86, CHCl3).
(6S,9R,14aS,15R)-13-hydroxy-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-trimethyl-
5,6,9,14,14a,15-hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-7-one 
(S15). In a nitrogen-filled glovebox, Buchwald’s dimer (16.4 mg, 0.022 mmol, 0.50 equiv) and 
5-[di(1-adamantyl)phosphino]-1′,3′,5′-triphenyl-1′H-[1,4′]bipyrazole (AdBippyPhos, 58.9 mg, 
0.089 mmol, 2.00 equiv) were weighed into a scintillation vial and dioxane (4.0 mL) was added. 
The vial was sealed with electrical tape and removed from the glovebox, sonicated briefly, and 
returned to the glovebox.  The resulting tan solution was then transferred to a scintillation vial 
containing bis-tetrahydroisoquinoline S13 (23.0 mg, 0.045 mmol, 1.00 equiv) and CsOH•H2O 
(74.7 mg, 0.045 mmol, 10.0 equiv), followed by a 0.5 mL rinse (4.5 mL total volume, 0.01 M). 
The vial was sealed, removed from the glovebox, and placed in a preheated 90 ºC oil bath.  After 
3 h, the vial was removed and allowed to cool fully to room temperature prior to removing the 
seal.  Acetic acid (23 µL, 0.401 mmol, 9 equiv) was added to quench remaining CsOH and the 
contents of the vial were transferred to a roundbottom flask, to which silica gel was added direct-
ly to dry load the crude mixture onto a silica gel column.  The solution was concentrated, and the 
product was purified by column chromatography (2–4–6–8% MeOH + CH2Cl2: no NEt3 added). 
Colorless solid, 14.4 mg, 0.029 mmol, 65% yield. Note:  Based on the 1H NMR spectrum of the 
isolated product, there is approximately 20% of an additional side product. 1H NMR (500 MHz, 
CDCl3) δ 6.55 (s, 1H), 5.85 (dd, J = 6.7, 4.1 Hz, 1H), 4.15 – 3.98 (m, 2H), 3.94 (d, J = 2.5 Hz, 
7H), 3.89 (s, 4H), 3.81 (s, 4H), 3.50 (dd, J = 11.0, 4.2 Hz, 1H), 3.34 – 3.22 (m, 3H), 3.07 (dd, J = 
17.6, 1.2 Hz, 1H), 2.60 (s, 3H), 2.37 (dd, J = 14.9, 12.6 Hz, 1H), 2.28 (s, 3H), 2.26 (s, 3H); 13C 
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NMR (101 MHz, CDCl3) δ 173.3, 157.3, 156.8, 150.0, 146.3, 143.7, 128.7, 125.3, 119.8, 118.8, 
118.3, 117.4, 107.2, 69.1, 61.3, 60.9, 60.4, 60.2, 60.2, 58.1, 56.0, 52.6, 40.0, 29.8, 26.1, 24.0, 9.1; 
IR (thin film, NaCl): 3318.3, 2935.3, 1621.7, 1607.9, 1587.1, 1463.4, 1455.5, 1354.7, 1272.0, 
1123.1, 1068.6, 755.2; HRMS (ESI-TOF) calc’d for [M+H]+ C27H35N2O7 =499.2439, found 
499.2449; [α]D = –87.2º (c = 1.03, CHCl3). 
(6S,7R,9R,14aS,15R)-13-hydroxy-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-
trimethyl-6,7,9,14,14a,15-hexahydro-5H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinoline-
7-carbonitrile (32). In an oven-dried 1-dram vial, LiAlH4 solution (1.0 M in THF, 1 mL, 1.0 
mmol) was cooled to 0 ºC.  A solution of ethyl acetate (115 µL, 1.18 mmol) in 1 mL THF was 
added slowly, and the resulting solution was stirred 30 min at 0 ºC, providing a 0.47 M solution 
of Li(EtO)2AlH2 in THF.  bis-Tetrahydroisoquinoline S15 (14.4 mg, 28.9 µmol, 1.0 equiv) was 
dissolved in THF (1.5 mL, 0.02 M) and the resulting solution was cooled to 0 ºC.  A solution of 
Li(EtO)2AlH2 (0.47 M in THF, 0.92 mL, 0.43 mmol, 15.0 equiv) was added slowly, resulting in 
extensive evolution of H2.  After stirring 20 min, LCMS showed complete consumption of S15, 
so the reaction was quenched with acetic acid (34.7 µL, 0.607 mmol, 21 equiv) and aqueous 
potassium cyanide (4.8 M, 36.1 µL, 0.173 mmol, 6.0 equiv) was added, followed by celite and 
anhydrous Na2SO4 (roughly 500 mg each).  The solution was diluted with 3 mL THF and stirred 
for 12 h, warming to room temperature.  At this stage, LCMS revealed some unreacted starting 
material, so the reaction was stirred at 50°C for an additional 3 hours. ~1 g of K2CO3 was added, 
followed by celite. The suspension was filtered through celite, rinsed with EtOAc, and concen-
trated. The product was purified by preparative HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/
min, monitor wavelength = 230 nm, 40–60% MeCN over 7 min, ramp to 95% MeCN over 0.5 
min, hold at 95% for 2.5 min for a total run time of 10 min.  Product 32 has tR = 5.1 min).  Color-
less solid, 5.1 mg, 10.0 µmol, 35% yield. 1H NMR (600 MHz, CDCl3) δ 6.37 (s, 1H), 4.09 (d, J = 
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2.4 Hz, 1H), 4.07 (t, J = 4.6 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.77 (s, 3H), 3.73 (s, 3H), 3.65 – 
3.62 (m, 1H), 3.53 (dd, J = 10.9, 4.5 Hz, 1H), 3.43 (dt, J = 7.8, 1.5 Hz, 1H), 3.27 (dt, J = 12.0, 
2.7 Hz, 1H), 3.16 – 3.09 (m, 2H), 2.94 (dd, J = 15.1, 2.7 Hz, 1H), 2.50 (d, J = 18.2 Hz, 1H), 2.39 
(s, 3H), 2.13 (s, 3H), 2.12 (s, 3H), 2.10 (d, J = 12.3 Hz, 1H), 1.99 (dd, J = 15.1, 12.1 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 156.6, 156.1, 149.6, 146.3, 143.3, 130.4, 125.8, 119.3, 118.9, 
118.1, 117.8, 116.1, 107.6, 66.2, 63.6, 61.4, 60.8, 60.5, 60.1, 58.5, 56.4, 55.9, 55.8, 41.9, 26.1, 
21.8, 9.2, 8.9; IR (thin film, NaCl): 3443.9, 2937.0, 2359.2, 1606.3, 1463.3, 1417.5, 1354.4, 
1263.8, 1190.8, 1122.4, 1070.4, 983.0, 911.3, 732.7; HRMS (ESI-TOF) calc’d for [M+] 
C28H36N3O6 = 510.2599, found 510.2589; [α]D = +36.4º (c = 0.36, CHCl3). 
(6S,9R,14aS,15R)-1-hydroxy-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-trimethyl- 
5,6,9,14,14a,15-hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-7-one 
(S16). In a nitrogen-filled glovebox, Buchwald’s dimer (6.8 mg, 9.2 µmol, 0.50 equiv) and 5-
[di(1-adamantyl)phosphino]-1′,3′,5′-triphenyl-1′H-[1,4′]bipyrazole (AdBippyPhos, 24.4 mg, 
0.037 mmol, 2.00 equiv) were weighed into a scintillation vial and dioxane (1.6 mL) was added. 
The vial was sealed with electrical tape and removed from the glovebox, sonicated briefly, and 
returned to the glovebox.  The resulting tan solution was then transferred to a 1-dram vial con-
taining bis-tetrahydroisoquinoline S14 (9.5 mg, 0.018 mmol, 1.00 equiv) and CsOH•H2O (30.9 
mg, 0.184 mmol, 10.0 equiv), followed by a 0.2 mL rinse (1.8 mL total volume, 0.01 M).  The 
vial was sealed, removed from the glovebox, and placed in a preheated 90 ºC oil bath.  After 3 h, 
the vial was removed and allowed to cool fully to room temperature prior to removing the seal. 
Acetic acid (9.5 µL, 0.166 mmol, 9 equiv) was added to quench remaining CsOH and the con-
tents of the vial were transferred to a scintillation vial, to which silica gel was added directly to 
dry load the crude mixture onto a silica gel column.  The solution was concentrated, and the 
product was purified by column chromatography (2–4–6–8% MeOH + CH2Cl2: no NEt3 added). 
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Due to a significant amount of impurities present in the sample, the isolated product was repuri-
fied using preparative HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength 
= 235 nm, 25–55% MeCN over 10 min, ramp to 95% MeCN over 0.5 min, hold at 95% for 2.5 
min for a total run time of 13 min.  Product S16 has tR = 5.1 min). White solid, 1.7 mg, 3.41 
µmol, 19% yield. 1H NMR (400 MHz, CDCl3) δ 6.72 (s, 1H), 5.81 (dd, J = 7.2, 3.6 Hz, 1H), 5.65 
(s, 1H), 4.27 (dd, J = 3.7, 1.3 Hz, 1H), 4.02 (dt, J = 12.7, 2.9 Hz, 1H), 3.90 (s, 3H), 3.78 (s, 3H), 
3.77 (s, 3H), 3.76–3.73 (m, 1H), 3.68 (s, 3H), 3.45 (dd, J = 11.0, 4.1 Hz, 1H), 3.22 (dd, J = 10.6, 
7.2 Hz, 1H), 3.13 (dd, J = 18.0, 6.7 Hz, 1H), 3.07 – 2.93 (m, 2H), 2.47 – 2.32 (m, 4H), 2.24 (s, 
3H), 2.23 – 2.20 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 173.6, 149.9, 149.8, 149.6, 143.7, 
143.0, 132.2, 131.7, 124.8, 124.7, 123.4, 123.0, 115.9, 69.4, 61.1, 60.7, 60.5, 60.0, 59.7, 59.2, 
55.2, 52.7, 40.2, 31.8, 24.8, 15.9, 9.8; IR (thin film, NaCl): 3423.5, 2936.4, 1628.4, 1438.5, 
1412.0, 1325.6, 1259.5, 1235.8, 1109.0, 1080.0, 1052.4, 1006.2, 730.9; HRMS (ESI-TOF) calc’d 
for [M+H]+ C27H35N2O7 =499.2439, found 499.2439; [α]D = –45.8º (c = 0.10, CHCl3).  
Note:  In addition to the desired product S16, we were also able to isolate and assign the struc-
ture of side product S17.  S17 presumably arises from palladium-mediate oxidative deformyla-
tion.  Similar byproducts have been identified by LCMS in other runs, but have neither been iso-
lated nor quantified. 
(6S,14aS,15R)-2,4,10,11-tetramethoxy-3,12,16-trimethyl-5,6,9,14,14a,15-hexahydro 
-7H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-7-one (S17). Isolated from preparative 
HPLC as described above. Product S17 has tR = 11.3 min. Colorless solid, 0.9 mg, 1.99 µmol, 
11% yield. 1H NMR (400 MHz, CDCl3) δ 6.67 (s, 1H), 6.38 (s, 1H), 4.66 (d, J = 18.7 Hz, 1H), 
4.55 (d, J = 18.7 Hz, 1H), 4.05 (ddd, J = 12.2, 4.8, 2.7 Hz, 1H), 3.87 (dd, J = 4.7, 1.2 Hz, 1H), 
3.85 (s, 3H), 3.82 (s, 4H), 3.78 (s, 3H), 3.70 (s, 3H), 3.10 (dd, J = 17.9, 7.1 Hz, 1H), 2.97 – 2.88 
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(m, 1H), 2.69 (dd, J = 15.0, 2.7 Hz, 1H), 2.48 (s, 3H), 2.45 – 2.34 (m, 1H), 2.21 (s, 3H), 2.13 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 171.0, 157.3, 156.6, 149.7, 130.6, 129.5, 129.1, 124.7, 
123.4, 119.6, 119.1, 107.0, 60.7, 60.2, 59.5, 55.9, 55.8, 40.6, 40.1, 33.7, 22.8, 15.8, 9.1; IR (thin 
film, NaCl): 2935.3, 2857.5, 2361.9, 2344.3, 1653.9, 1638.1, 1609.7, 1458.2, 1448.3, 1412.7, 
1327.2, 1123.8, 1078.4, 1000.9, 731.2; HRMS (ESI-TOF) calc’d for [M+H]+ C26H33N2O5 
=453.2384, found 453.2379; [α]D = –123.4º (c = 0.06, CHCl3). 
(6S,7R,9R,14aS,15R)-1-hydroxy-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-tri-
methyl-6,7,9,14,14a,15-hexahydro-5H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinoline-7-
carbonitrile (33). In an oven-dried 1-dram vial, LiAlH4 solution (1.0 M in THF, 1 mL, 1.0 
mmol) was cooled to 0 ºC.  A solution of ethyl acetate (115 µL, 1.18 mmol) in 1 mL THF was 
added slowly, and the resulting solution was stirred 30 min at 0 ºC, providing a 0.47 M solution 
of Li(EtO)2AlH2 in THF.  bis-Tetrahydroisoquinoline S16 (2.2 mg, 4.41 µmol, 1.0 equiv) was 
dissolved in THF (0.2 mL, 0.02 M) and the resulting solution was cooled to 0 ºC.  A solution of 
Li(EtO)2AlH2 (0.47 M in THF, 141 µL, 66.2 µmol, 15.0 equiv) was added slowly, resulting in 
extensive evolution of H2.  After stirring 20 min, LCMS showed complete consumption of S16, 
so the reaction was quenched with acetic acid (5.3 µL, 92.7 µmol, 21 equiv). Aqueous potassium 
cyanide (4.8 M, 5.5 µL, 26.5 µmol, 6.0 equiv) was added, followed by celite, anhydrous Na2SO4 
(roughly 100 mg each), and 0.4 mL of THF. The reaction was warmed to room temperature at 
stirred for 12 h. ~150 mg of K2CO3 and celite were added. The suspension was filtered through 
celite, rinsed with EtOAc, and concentrated. The product was purified by preparative HPLC 
(MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 230 nm, 40–70% MeCN 
over 10 min, ramp to 95% MeCN over 0.5 min, hold at 95% for 2.5 min for a total run time of 13 
min.  Product 33 has tR = 4.7 min).  Colorless solid, 0.7 mg, 1.4 µmol, 31% yield. 1H NMR (400 
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MHz, CDCl3) δ 6.65 (s, 1H), 5.52 (s, 1H), 4.15 (s, 1H), 4.07 (d, J = 3.0 Hz, 2H), 3.87 (s, 3H), 
3.75 (t, J = 0.9 Hz, 7H), 3.70 (s, 3H), 3.56 (d, J = 8.6 Hz, 2H), 3.43 – 3.31 (m, 2H), 3.10 (dd, J = 
18.5, 7.8 Hz, 1H), 2.80 (dd, J = 15.4, 2.5 Hz, 1H), 2.50 (d, J = 18.5 Hz, 1H), 2.34 (s, 3H), 2.23 
(s, 3H), 2.20 (s, 4H); 13C NMR (101 MHz, CDCl3) δ 155.5, 149.2, 148.7, 143.6, 143.3, 142.1, 
131.8, 131.2, 125.2, 124.9, 123.5, 118.1, 116.9, 66.0, 61.1, 61.1, 60.5, 60.2, 60.1, 58.7, 57.5, 
56.6, 55.3, 41.9, 32.0, 21.8, 15.8, 9.8; IR (thin film, NaCl): 3400.3, 2930.0, 2858.5, 2350.5, 
2250.0, 1663.8, 1458.2, 1411.7, 1327.3, 1308.1, 1261.2, 1105.8, 1080.3, 1056.6, 1009.6, 910.8, 
800.7, 733.4; HRMS (ESI-TOF) calc’d for [M+] C28H36N3O6 = 510.2599, found 510.2596; [α]D 
= –21.8º (c = 0.05, CHCl3). 
(6S,7R,9R,14aS,15R)-1,13-dihydroxy-9-(hydroxymethyl)-2,4,10,11-tetramethoxy-3,12,16-
trimethyl-6,7,9,14,14a,15-hexahydro-5H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinoline-
7-carbonitrile (34).  In an oven-dried vial, LiAlH4 solution (1.0 M in THF, 2 mL, 2.0 mmol) was 
cooled to 0 ºC.  A solution of ethyl acetate (230 µL, 2.35 mmol) in 2 mL THF was added slowly, 
and the resulting solution was stirred 30 min at 0 ºC, providing a 0.47 M solution of 
Li(EtO)2AlH2 in THF.  bis-Tetrahydroisoquinoline 29 (49.0 mg, 0.095 mmol, 1.0 equiv) was dis-
solved in THF (4.8 mL, 0.02 M) and the resulting solution was cooled to 0 ºC.  A solution of 
Li(EtO)2AlH2 (0.47 M in THF, 3.0 mL, 1.43 mmol, 15.0 equiv) was added slowly, resulting in 
extensive evolution of H2.  After stirring 45 min, the reaction was quenched with acetic acid (115 
µL, 2.00 mmol, 21 equiv) and aqueous potassium cyanide (4.8 M, 120 µL, 0.571 mmol, 6.0 
equiv) was added, followed by celite and anhydrous Na2SO4 (roughly 1 g each).  The solution 
was diluted with 8 mL THF and stirred 10 h, warming to room temperature.  More celite was 
added, and the suspension was filtered through celite, rinsing with EtOAc.  The filtrate was 
transferred to a roundbottom flask and was concentrated.  At this stage, LCMS revealed a ~4:1 
mixture of product 34 and starting material 29, so the crude mixture was resubjected to the re-
S !54
then, AcOH, aq. KCN MeO
OMe
Me
N
(50% yield)
N
OH
CN
H
OMe
Me
OMe
MeO
OMe
Me
N
N
OH
O
H
OMe
Me
OMe
Me
OH
HO
Me Li(EtO)2AlH2, THF, 0 ºC
OH
HO
3429
duction conditions, using 3 mL THF as the reaction solvent and 1 mL of freshly prepared 
Li(EtO)2AlH2 solution.  After 10 min, LCMS showed very little conversion of the remaining 
starting material, with some over-reduced product (m/z = 501).  The reaction mixture was 
quenched and worked up as described above.  The product was purified by column chromatogra-
phy (50–75–100% EtOAc/hex, 200 mL each; product elutes in the 75% portion).  Colorless sol-
id, 25.2 mg, 47.9 µmol, 50% yield.  1H NMR (400 MHz, CDCl3) δ 4.19 (dD, J = 2.7, 1.1 Hz, 
1H), 4.00 – 4.05 (m, 2H), 3.81 (s, 3H), 3.751 (s, 3H), 3.749 (s, 3H), 3.70 (s, 3H), 3.56 (dd, J = 
10.9, 4.4 Hz, 1H), 3.40 (ddd, J = 7.5, 2.5, 1.2 Hz, 1H), 3.31 (dt, J = 12.1, 2.7 Hz, 1H), 3.18 (d, J 
= 9.4 Hz, 1H), 3.13 (dd, J = 15.6, 2.7 Hz, 1H), 3.10 (dd, J = 18.6, 7.8 Hz, 1H), 2.51 (d, J = 18.6 
Hz, 1H), 2.34 (s, 3H), 2.22 (s, 3H), 2.09 (s, 3H), 1.85 (dd, J = 15.6, 12.0 Hz, 1H); 13C NMR (101 
MHz, CDCl3) δ 149.6, 148.7, 146.6, 143.7, 143.4, 143.1, 125.4, 123.5, 122.7, 118.1, 118.0, 
117.1, 116.7, 66.2, 61.2, 61.0, 60.8, 60.4, 60.2, 58.5, 57.1, 56.7, 55.2, 41.9, 25.4, 21.7, 9.8, 9.0; 
IR (thin film, NaCl): 3427.6, 2936.1, 2832.7, 2228.1, 1606.8, 1463.2, 1412.1, 1384.5, 1349.9, 
1319.9, 1300.9, 1251.3, 1218.1, 1191.3, 1150.7, 1107.7, 1070.1, 1001.7, 981.7, 907.7, 875.4, 
829.8, 754.4; HRMS (ESI-TOF) calc’d for [M+] C28H35N3O7 = 525.2475, found 525.2471; [α]D 
= +22.9º (c = 0.5, CHCl3). 
Preparation and Crystal Structure Analysis of 27 (sample No.: P17208). 
(6S,9R,14aS,15R)-16-((4-bromophenyl)sulfonyl)-9-(hydroxymethyl)-2,4,10,11-tetra-
methoxy-3,12-dimethyl-5,6,9,14,14a,15-hexahydro-7H-6,15-epiminobenzo[4,5]azocino[1,2-
b]isoquinolin-7-one (27).  bis-Tetrahydroisoquinoline 6 (45 mg, 0.096 mmol, 1.0 equiv, 88% 
ee), 4-dimethylaminopyridine (DMAP, 1.2 mg, 0.0096 mmol, 0.10 equiv), and p-bromophenyl-
sulfonyl chloride (27 mg, 0.105 mmol, 1.10 equiv) were dissolved in CH2Cl2 (2 mL, 0.05 M) and 
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diisopropylethylamine (DIPEA, 33 µL, 0.192 mmol, 2.0 equiv) was added.  The solution was 
stirred 2 h, at which time LCMS revealed full conversion to product 27.  The reaction was 
quenched by the addition of 1M HCl.  The layers were separated and the aqueous phase was ex-
tracted with CH2Cl2.  The combined organic phases were washed with brine, dried over Na2SO4 
and concentrated.  The product was purified by column chromatography (1% MeOH/CH2Cl2 + 
1% NEt3).  Colorless solid, 61.0 mg, 0.089 mmol, 92% yield.  1H NMR (400 MHz, CDCl3) δ 
7.55 (d, J = 8.7 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 6.73 (s, 1H), 6.35 (s, 1H), 5.70 (dd, J = 6.3, 
4.3 Hz, 1H), 5.07 (dd, J = 3.5, 1.6 Hz, 1H), 4.74 (dt, J = 7.0, 1.3 Hz, 1H), 4.01 (dt, J = 12.7, 2.9 
Hz, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.77 (s, 3H), 3.49 (s, 3H), 3.41 (dt, J = 10.4, 4.9 Hz, 1H), 
3.19 (dt, J = 11.2, 5.6 Hz, 1H), 3.03 (dd, J = 17.6, 1.3 Hz, 1H), 2.77 (dd, J = 14.4, 2.6 Hz, 1H), 
2.71 (dd, J = 17.6, 6.9 Hz, 1H), 2.62 (t, J = 13.4 Hz, 1H), 2.49 (t, J = 5.6 Hz, 1H), 2.24 (s, 3H), 
2.09 (s, 3H).  X-ray quality crystals were obtained by allowing the slow evaporation of an iso-
propanol solution of 27.  The major enantiomer of the mixture is shown below. 
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Table S5.  Crystal data and structure refinement for P17208_sq. 
Identification code  P17208_sq 
Empirical formula  C32 H35 Br N2 O8 S 
Formula weight  687.59 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P21212 
Unit cell dimensions a = 29.7321(15) Å a= 90°. 
 b = 10.3172(5) Å b= 90°. 
 c = 12.6857(5) Å g = 90°. 
Volume 3891.4(3) Å3 
Z 4 
Density (calculated) 1.174 Mg/m3 
Absorption coefficient 2.307 mm-1 
F(000) 1424 
Crystal size 0.250 x 0.150 x 0.050 mm3 
Theta range for data collection 2.972 to 74.895°. 
Index ranges -37<=h<=37, -12<=k<=12, -15<=l<=13 
Reflections collected 45082 
Independent reflections 7958 [R(int) = 0.0739] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.5857 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7958 / 70 / 430 
Goodness-of-fit on F2 1.116 
Final R indices [I>2sigma(I)] R1 = 0.0560, wR2 = 0.1328 
R indices (all data) R1 = 0.0611, wR2 = 0.1354 
Absolute structure parameter 0.140(9) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.650 and -0.545 e.Å-3 
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Cell Culture and Proliferation Assays 
Cell lines, cell culture, and reagents:  
A panel of 29 cell lines, representing 4 major cancer types (lung, colon breast and ovari-
an), was assayed for response to THIQ agents. Cells were cultured in appropriate culture 
media (e.g., RPMI 1640, DMEM, L-15) supplemented with 10% to 15% heat-inactivated 
fetal bovine serum (FBS), 2 mmol/L glutamine, and 1% penicillin G-streptomycin-fungi-
zone solution (PSF, Irvine Scientific) as previously described (41).  Cells were routinely 
assessed for mycoplasma contamination using a multiplex PCR method and STR profil-
ing by the GenePrint 10 System (Promega) was used for cell-line authentication.  
In vitro proliferation assays:  
Response to THIQ agents was measured by a six-day proliferation assay.  Stock solutions 
of THIQ agents were prepared at 10 mM in DMSO. Cells were seeded in 48-well plates 
at a seeding density previously determined to maximize growth over a 6-day treatment 
window.  After 24 hours, the cells were treated with six 1:10 (34) or 1:5 (30–33) dilutions 
of inhibitor starting at 1 µM.  Control wells were imaged at this time for baseline cell 
counts.  After six days of treatment cells were counted on a custom automation platform 
designed by Tecan.  This robotic system trypsinizes adherent cells, centrifuges cells to the 
bottom of the wells and counts cells via brightfield image segmentation on a Synentec 
Cellavista imaging system.  IC50 values for each molecule were calculated by fitting 
curves to data points from each dose–response assay using the Proc NLIN function in 
SAS for Windows version 9.2 (SAS Institute, Inc.). 
S !58
Biological Evaluation of Non-Natural Analogs 
Table S12.  IC50’s (nM) of compounds 30–34 (all data in µM; data listed as 1000 µM are  
≥1000 µM). 
S !59
30 31 32 33 34
H810 Lung 260 ND 260 210 110
A427 Lung 660 1000 880 210 340
H1836 Lung 470 1000 700 280 490
H226 Lung 1000 ND 770 210 660
H441 Lung 1000 ND 980 270 740
H1437 Lung 1000 ND 1000 740 760
H647 Lung 1000 1000 1000 540 770
NCIH747 Colon 1000 1000 290 150 120
SW837 Colon 910 1000 890 140 230
SW480 Colon 1000 ND 720 190 370
LS174t Colon 1000 1000 1000 260 610
SNUC1 Colon 1000 ND 820 500 730
SKCO1 Colon 1000 1000 1000 790 780
SW48 Colon 1000 1000 720 120 810
OVCAR3 Ovarian 1000 1000 1000 150 120
ES2 Ovarian 1000 1000 410 200 170
OV207 Ovarian 1000 1000 970 250 170
OVTOKO Ovarian 1000 1000 860 210 420
RMG1 Ovarian 1000 1000 990 200 520
RMUGS Ovarian 1000 1000 1000 300 550
OVCAR5 Ovarian 1000 ND 310 220 650
EFO21 Ovarian 1000 1000 1000 240 780
MB468 Breast 1000 ND 470 140 210
ZR751 Breast 1000 ND 330 180 230
EFM19 Breast 460 ND 1000 140 230
MB453 Breast 260 ND 1000 250 350
HCC1806 Breast 1000 ND 560 190 380
T47D Breast 1000 ND 1000 210 540
COLO824 Breast 230 ND 260 200 790
Table S13. Geometric mean of IC50 values and their statistics
S !60
Compound Geometric Mean Median Maximum Minimum
Carfilzomib .004 .005 .020 .001
Cisplatin .202 .199 .799 .028
MK8745 .360 .380 1.000 0.079
MMAE .438 3.978 .077
.807 1.000 1.000 .225
1.000 1.000 1.000 1.000
.708 .891 1.000 .256
.233 .213 .787 .120
.397 .516 .812 .109
.405
30
31
32
33
34
IC50 Statistics (all numbers in µM)
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 13C NMR (101 MHz, CDCl3) of compound S2. 
 
1H NMR (400 MHz, CDCl3) of compound S2. 
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 13C NMR (101 MHz, CDCl3) of compound 11. 
 
1H NMR (400 MHz, CDCl3) of compound 11. 
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 13C NMR (126 MHz, CDCl3) of compound 13. 
 
Infrared spectrum (Thin Film, NaCl) of compound 13. 
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 13C NMR (101 MHz, CDCl3) of compound 9. 
 
Infrared spectrum (Thin Film, NaCl) of compound 9. 
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 13C NMR (101 MHz, CDCl3) of compound S4. 
 
1H NMR (400 MHz, CDCl3) of compound S4. 
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 13C NMR (101 MHz, CDCl3) of compound S5. 
 
1H NMR (400 MHz, CDCl3) of compound S5. 
 
S5
MeO
OMe
Me O NHi-Pr
O
TMS
   
 
S69
	



	
















	


	


	


	

	


	




	



	



	



	





	




	




	




	





	




	





	





	




	





	





	


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 13C NMR (101 MHz, CDCl3) of compound 14. 
 
1H NMR (400 MHz, CDCl3) of compound 14. 
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 13C NMR (101 MHz, CDCl3) of compound 16. 
 
Infrared spectrum (Thin Film, NaCl) of compound 16. 
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 13C NMR (101 MHz, CDCl3) of compound 10. 
 
Infrared spectrum (Thin Film, NaCl) of compound 10. 
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19F NMR (282 MHz, CDCl3) of compound 10 
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 13C NMR (101 MHz, CDCl3) of compound 18. 
 
Infrared spectrum (Thin Film, NaCl) of compound 18. 
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13C NMR (101 MHz, CDCl3) of compound S8. 
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 13C NMR (101 MHz, CDCl3) of compound S6. 
 
Infrared spectrum (Thin Film, NaCl) of compound S6. 
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 13C NMR (101 MHz, CDCl3) of compound S7. 
 
Infrared spectrum (Thin Film, NaCl) of compound S7. 
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 13C NMR (101 MHz, CDCl3) of compound S9 and S10. 
 
Infrared spectrum (Thin Film, NaCl) of compound S9 and S10. 
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 13C NMR (101 MHz, CDCl3) of compound 8DCM. 
 
Infrared spectrum (Thin Film, NaCl) of compound 8DCM. 
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Infrared spectrum (Thin Film, NaCl) of compound 20. 
 
 13C NMR (101 MHz, CDCl3) of compound 20. 
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Infrared spectrum (Thin Film, NaCl) of compound 21. 
 
 13C NMR (101 MHz, CDCl3) of compound 21. 
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 13C NMR (126 MHz, CDCl3) of compound 6. 
 
Infrared spectrum (Thin Film, NaCl) of compound 6. 
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 13C NMR (126 MHz, CDCl3) of compound S11. 
 
Infrared spectrum (Thin Film, NaCl) of compound S11. 
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 13C NMR (126 MHz, CDCl3) of compound 28. 
 
Infrared spectrum (Thin Film, NaCl) of compound 28. 
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 13C NMR (126 MHz, CDCl3) of compound 29. 
 
Infrared spectrum (Thin Film, NaCl) of compound 29. 
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 13C NMR (101 MHz, CDCl3) of compound 34. 
 
Infrared spectrum (Thin Film, NaCl) of compound 34. 
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 13C NMR (101 MHz, CDCl3) of compound 3. 
 
Infrared spectrum (Thin Film, NaCl) of compound 3. 
 
   
 
S105








	















	





























	



	
	
	
	


	


















	







  
 1 H
 N
M
R
 (4
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
30
. 
 
 
M
eOM
e
N
N
OH
CN
H
OM
e
M
e O
M
e
O
O
30
M
eO
OH
   
 
S106


	

	













	







	

























	












	

	

	









	











	
















  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 13C NMR (101 MHz, CDCl3) of compound 30. 
 
Infrared spectrum (Thin Film, NaCl) of compound 30. 
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 13C NMR (101 MHz, CDCl3) of compound 1. 
 
Infrared spectrum (Thin Film, NaCl) of compound 1. 
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 13C NMR (101 MHz, CDCl3) of compound 31. 
 
Infrared spectrum (Thin Film, NaCl) of compound 31. 
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 13C NMR (101 MHz, CDCl3) of compound S13. 
 
Infrared spectrum (Thin Film, NaCl) of compound S13. 
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 13C NMR (101 MHz, CDCl3) of compound S14. 
 
Infrared spectrum (Thin Film, NaCl) of compound S14. 
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 13C NMR (101 MHz, CDCl3) of compound S15. 
 
Infrared spectrum (Thin Film, NaCl) of compound S15. 
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 13C NMR (101 MHz, CDCl3) of compound 32. 
 
Infrared spectrum (Thin Film, NaCl) of compound 32. 
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 13C NMR (101 MHz, CDCl3) of compound S16. 
 
Infrared spectrum (Thin Film, NaCl) of compound S16. 
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 13C NMR (101 MHz, CDCl3) of compound S17. 
 
Infrared spectrum (Thin Film, NaCl) of compound S17. 
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 13C NMR (101 MHz, CDCl3) of compound S33. 
 
Infrared spectrum (Thin Film, NaCl) of compound S33. 
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